SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions July category listing 07/06

20060166858 - Bile-acid conjugates providing for sustained systemic concentration of drugs: This invention is directed to compounds that provide for sustained systemic concentrations of therapeutic or prophylactic agents following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using such compounds....

20060166859 - Compounds and compositions for delivering active agents: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well....

20060166861 - Inclusion compound of porphyrin metal complex and albumin: where R1 is a cyclohexyl group or the like; R2 represents a substituent; M represents a transition metal atom or metal ion belonging to Groups 6 to 10 of the periodic table; X− represents a halogen ion; and the number of X− is obtained by subtracting 2 from a valence...

20060166863 - Inhibitor and stimulator of stem cell proliferation and uses thereof: Disclosed and claimed are methods for the isolation and use of stem cell modulating factors for regulating stem cell cycle and for accelerating the post-chemotherapy peripheral blood cell recovery. Also disclosed and claimed are the inhibitors and stimulators of stem cell proliferation....

20060166864 - Methods for modulating telomerase activity: Disclosed herein are engineered zinc finger proteins which bind to telomeric structures; methods for their design, synthesis and use; and cells comprising a telomere-binding zinc finger protein. Methods for modulating telomerase activity using telomere-binding zinc finger proteins are also provided....

20060166862 - Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation: An agent, composition and method for the treatment, prophylaxis and/or diagnosis of proliferative disorders, which is highly and efficiently absorbed at the site of abnormal cellular proliferation is disclosed....

20060166860 - Zinc transporter compositions for the treatment of cardiovascular diseases: The present invention relates to the use of ZnT-1, originally described as a zinc transporter, in the regulation of L-type calcium channels (LTCC). In this study, the inventors have unexpectedly demonstrated that ZnT-1 physically interacts with LTCC, regulating its function. Most importantly, the inventors have shown that ZnT-1 can regulate...

20060166866 - Cell adhesion inhibitors: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and...

20060166865 - Methods and compositions for treating flaviviruses and pestiviruses: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided....

20060166867 - Novel conjugates of polysaccharides and uses thereof: Novel conjugates composed of a saccharide-containing moiety (e.g., aminoglycosides) covalently linked to a moiety containing two or more basic amino acid residues (e.g., a polyarginine) and processes of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing these conjugates and uses of these conjugates as antiviral and antibacterial agents....

20060166869 - Novel use of lipopeptide preparations: The invention relates to the use of lipopeptide preparations as anti-tilted-peptide agents, which are able to inhibit or limit the destabilization effect of tilted peptides on hydrophobic/hydrophilic interfaces, for instance on membranes. The lipopeptides include surfactins, iturins, and fengycins. The invention also relates to a process for the production of...

20060166868 - Vegf peptides and their use: A novel peptide having the amino acid sequence SCKNTDSRCKARQLELNERTCRCDKPRR or a fragment thereof that substantially retains NP-1 antagonist activity, in cyclic form, is proposed for use in therapy....

20060166886 - Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction: A composition comprising an albumin-based colloid and its use in treating hypovolemic conditions such as capillary leak syndrome and shock are disclosed....

20060166880 - Control of function of intracellular ca ion: Analysis of substance capable of binding with inositol-1,4,5-triphosphate (IP3) receptor (IP3R), preferably with a regulation domain of IP3R; analysis of the function of IP3R; and establishing of a method of treatment or diagnosis for various malfunctions and diseases associated with IP3R. In particular, control of the activity of intracellular Ca2+...

20060166876 - Delocalization molecules and use thereof: The invention relates to delocalization molecules, methods for the production thereof, and the use thereof as medicaments, especially for treating tumors....

20060166872 - Fp receptor antagonists or pgf2 alpha antagonists for treating menorrhagia: A method of treating or preventing menorrhagia in an female individual the method comprising administering to the individual at least one agent that prevents PGP2α having its effect on the FP receptor. Optionally, an inhibitor of PGES and/or an antagonist of EP2 or EP4 is also administered....

20060166874 - Fvii or fviia variants having increased clotting activity: The present invention relates to novel Factor VII or VIIa variants comprising a substitution in at least one position selected from the group consisting of L39, 142, S43, K62, L65, F71, E82 and F275. Such variants exhibit increased clotting activity as compared to human wild-type Factor VIIa. The present invention...

20060166882 - Liquid, aqueous pharmaceutical composition of factor vii polypeptides: The present invention is directed to liquid, aqueous pharmaceutical compositions containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome, e.g., bleeding disorders, including those caused by...

20060166871 - Medical compositions containing ghrelin: It is provided a pharmaceutical composition stably containing ghrelin or its derivative, which is an endogenous growth hormone secretagogue (GHS) to a growth hormone secretagogue-receptor (GHS-R), comprising a aqueous solution containing the ghrelins having pH range of 2 to 7, wherein the aqueous solution having pH range of 2 to...

20060166881 - Membrane-permeant peptide complexes for treatment of sepsis: Methods and compositions for treating sepsis using cell membrane-permeant peptide conjugate covalent compounds having target cell specificity are provided....

20060166887 - Method of inducing neuronal production in the brain and spinal cord: The present invention relates to methods of inducing neuronal production in the brain, recruiting neurons to the brain, and treating a neurodegenerative condition by providing a nucleic acid construct encoding a neurotrophic factor, and injecting the nucleic acid construct intraventricularly into a subject's brain....

20060166877 - Methods of protecting against radiation damage using alpha thymosin: Damage to cells and/or a subject caused by radiation is treated or prevented by administration of an alpha thymosin peptide....

20060166883 - Novel antimicrobial peptides based on tripeptide repeats: The invention described herein relates to compositions of novel antimicrobial peptides that comprise hydrophobic and cationic residues, based on monomeric tri-peptide units. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof...

20060166878 - Peptide antagonists of vascular endothelial growth factor: The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and...

20060166873 - Preventive/remedy for arteriosclerosis: A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of...

20060166884 - Purified rhlgf-i/rhlgfbp-3 complexes and their method of manufacture: Complexes of IGF-I and IGFBP-3 with new levels of purity are provided. Chromatographic techniques have been developed that remove contaminants, such as mass and charge variants of IGFBP-3. The new techniques enable the production of high-quality pharmaceutical compositions comprising IGF-I/IGFBP-3 complexes....

20060166875 - Single chain recombinant t cell receptors: A single chain T cell receptor (scTCR) comprising an a segment constituted by a TCR α chain variable region sequence fused to the N terminus of a TCR α chain constant region extracellular sequence, a β segment constituted by a TCR β chain variable region fused to the N terminus...

20060166885 - Treatment and prevention of decubitus: Provided is a method for treating a subject suffering from, or at risk of suffering from, decubitus, the method comprising a step of administering erythropoietin (EPO), or a functional part, derivative or analogue thereof to the subject. In certain embodiments, the EPO has been recombinantly produced in host cells that...

20060166879 - Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders: A method and formulation are provided for the treatment of medical conditions associated with the formation and/or deposition of macromolecular aggregates, particularly those associated with adverse ocular conditions. The formulation contains a non-cytotoxic chelating agent containing at least three negatively charged chelating atoms and a charge-masking agent containing at least...

20060166870 - Treatment of glioblastoma with thymosin-alpha 1: Thymosin-α1 is used as an adjuvant in combination with carmustine (BCNU) as an effective treatment for malignant glioblastoma....

20060166888 - Leukocyte stimulating peptides: The present application describes peptides that stimulate arachidonic acid release in target cells. The application also discloses peptides that cause intracellular calcium release....

20060166889 - Insulin conjugates and methods of use thereof: The invention relates generally to chimeric peptides and compositions that facilitate the transport of insulin across biological membranes, methods for preparing the chimeric peptides, and a method for treating a subject suffering from diabetes....

20060166891 - Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia: The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral delivery and useful in the treatment and/or prevention of hypercholesterolemia, atherosclerosis and associated cardiovascular diseases....

20060166890 - Non-t cell binding peptides and their uses: The present invention provides a non-T cell binding peptide and its analogs used for the treatment of rheumatoid arthritis. The polypeptide therapeutic agent can specifically inhibit abnormal immune responses of the rheumatoid arthritis, and fundamentally control the progression of this disease with effect on the initiating factor of the disease...

20060166892 - Treatment of cell proliferative disorders with chlorotoxin: Disclosed is a method of treating cell proliferative disorders, such as cancer, with low doses of chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to inhibit or arrest abnormal cell growth....

20060166894 - Ace-inhibitors having antioxidant and no-donor activity: Multifonctional ACE inhibitor compounds are provided, that combine ACE-inhibiting activity with capability to scavenge superoxide and other reactive oxygen species, and that may further function as nitric oxide donors. The compounds are useful for preventing or treating various disorders, including cardiovascular, and diabetes associated disorders....

20060166893 - Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments: with the substituents as defined in the specification, having a calpain inhibiting activity and/or an activity which traps the reactive oxygen species useful for treating inflammatory and immunological diseases, cardio-vascular and cerebro-vascular diseases, disorders of the central or peripheral nervous system, osteoporosis, muscular dystrophy, proliferative diseases, cataract, rejection reactions following...

20060166896 - Novel indazole peptidomimetics as thrombin receptor antagonists: The invention is directed to novel indazole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted indazole peptidomimetics of...

20060166897 - Novel indazole peptidomimetics as thrombin receptor antagonists: The invention is directed to novel indazole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted indazole peptidomimetics of...

20060166895 - Retroviral protease inhibitors: N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease....

20060166898 - Fertilizer-compatible composition: This invention relates to compositions compatible with liquid fertilizers and methods of use thereof....

20060166901 - Compositions comprising o-acetylsalicyl derivatives of aminocarbohydrates and amino acids: The embodiments described herein include a composition and method of treatment using compositions that include at least one O-acetylsalicyl derivative. The compositions and methods are useful in preventing and treating disorders and syndromes associated with anyone of the nervous, vascular, musculoskeletal, or cutaneous systems....

20060166902 - Derivative of glucose and of vitamin f, compositions comprising it, uses and preparation process: An O-acyl product derived from glucose which may be obtained by partial or total esterification of glucose and of vitamin F, comprising a mixture of esters, for example, monoesters, of glucose and of at least one acid chosen from linoleic acid, oleic acid, palmitic acid and stearic acid, compositions, for...

20060166899 - Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents a single bond, a C1-6 alkylene group etc.; Z represents CO or SO2; R4 and...

20060166900 - Salt of morphine-6-glucuronide: Hydrobromide salt of morphine-6-β-D-glucuronide (M6G.HBr), a medicament, and a pharmaceutical composition comprising the M6G.HBr are disclosed. Methods of treating diseases using M6G.HBr, use of M6G.HBr as a medicament, in particular as an analgesic, are provided. Methods of making M6G.HBr and pharmaceutical compositions comprising the M6G.HBr also are provided....

20060166903 - Phosphocholine linked prodrug derivatives: Disclosed are compounds of general formula (I) that function as prodrugs, thereby increasing bioavailabilities of the linked therapeutic agents, wherein the LINKER is (i) substituted or unsubstituted alkyl, (ii) substituted or unsubstituted alkenyl, (iii) substituted or unsubstituted alkanoyl, (iv) substituted or unsubstituted alkenoyl wherein the double bond is cis, and...

20060166904 - 9a-azalides with anti-inflammatory activity: Macrolides with anti-inflammatory activity are described, and more particularly, 9a-azalides without cladinose in position 3 with anti-inflammatory activity, their pharmaceutically acceptable salts and pharmaceutical compositions that contain them as active principle....

20060166905 - Aivlosin for the treatment of disease due to brachyspira pilosicoli or ornithobacterium rhinotracheale: The invention relates to the use of Aivlosin for the treatment, prevention or control of diseases due to Brachyspira pilosicoli in pigs and Ornithobacterium rhinotrachelae in poultry....

20060166906 - 6-o-substituted erythromycin derivatives having improved gastrointestinal tolerance: e

20060166907 - Composition for the treatment of nasopharyngeal carcinoma and method of use thereof: Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one or more of a farnesyl transferase inhibitor and one or more of an anthracyline....

20060166916 - Composite polynucleic acid therapeutics: Compositions comprising therapeutic polynucleic acids and methods of use. The compositions comprise one or more polynucleic acids sequences having two or more features useful for treating diseases associated with cellular proliferation or growth....

20060166911 - Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a (pde11a): The invention provides a human PDE11A which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, cancer, liver disease and genito-urinary diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central...

20060166917 - Differentiation and/or proliferation modulating agents and uses therefor: The present invention discloses methods for modulating the differentiation and/or proliferation of mammary cells, especially of mammary epithelial cells, or for modulating the differentiation and/or proliferation of the lobuloalveolar system, or for modulating mammopoiesis and/or lactogenesis, or for modulating tumorigenesis in a cell which is associated with the reproductive system...

20060166924 - Gene therapeutics: Gene therapeutics to be used in treating diseases showing sensitivity to gene therapy, characterized by containing as the active ingredient an efficacious amount of a functional substance which has a function of having an affinity for a virus containing a gene usable in the gene therapy and another function of...

20060166915 - Human coagulation factor vii polypeptides: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment....

20060166923 - Immune stimulating composition comprising bacterial chromosomal dna fragments having methylated cpg sequences and non-toxic lipopolysaccharides: The present invention relates to immune stimulating composition comprising methylated bacterial chromosomal DNA fragments and non-toxic lipopolysaccharides. The composition of the present invention can be industrially applied the effective materials for treating cancers and adjuvant....

20060166914 - Method of nucleic acid infusion: A method of nucleic acid infusion, comprising the step (a) of bringing a nucleic acid, a hypertonic solution and cells into contact with each other and the step (b) of lowering the osmotic pressure of the hypertonic solution after the step (a). There is further provided a reagent for nucleic...

20060166908 - Nucloeside analogues and oligonucleotide derivative comprising nucleotide analogue thereof: where A represents a direct bond, an alkylene group having 1 to 4 carbon atoms, etc.; B represents an aromatic heterocyclic group which may have a substituent, etc.; R1, R2, R3 and R4 each represent a hydrogen atom, a protective group for an amino group, a protective group for a...

20060166920 - Oligonucleotide based therapeutics: The present invention relates to compositions comprising dsRNA. In particular, the present invention provides dsRNA comprising nucleotide sequence that is selectively complementary to bcl-xL mRNA sequence and that is not selectively complementary to bcl-xS mRNA sequence, recombinant nucleic acid comprising a vector and nucleic acid sequence for expressing bcl-xL dsRNA,...

20060166909 - Oligonucleotide inhibitors of mbd2/dna demethylase and uses thereof: Oligonucleotide inhibitors that inhibit expression of a mammalian MBD2/DNA demethylase (MBD2/dMTase) are provided. The oligonucleotide inhibitors can be used to inhibit the growth or proliferation of tumour cells in vitro and in vivo. The use of the oligonucleotide inhibitors in the treatment of cancer and methods of identifying potential target...

20060166922 - Polynucleotides targeted against the extended 5'-utr region of argininosuccinate synthase and uses thereof: The present invention is based in part on the discovery that the upstream open reading frame (uORF) in the extended 5′-untranslated region (5′-UTR) argininosuccinate synthase (AS) mRNA species is functional, and when functional, limits overall AS expression as well as nitric oxide (NO) production. Thus, the extended 5′-UTR AS mRNA...

20060166913 - Process for producing sirna: It is an object of the present invention to develop an inexpensive and simple method for transcription and synthesis of siRNA. The present invention provides an oligonucleotide, which at least comprises, in a direction from the 5′-terminus to the 3′-terminus: (1) an antisense sequence of a target nucleic acid sequence;...

20060166910 - Rna-interference by single-stranded rna molecules: The present invention relates to sequence and structural features of single-stranded (ss) RNA molecules required to mediate target-specific nucleic acid modifications by RNA-interference (RNAi), such as target mRNA degradation and/or DNA methylation....

20060166919 - Rnai inhibition of ctgf for treatment of ocular disorders: RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention....

20060166918 - Rnai modulation of mll-af4 and uses thereof: The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides....

20060166921 - Rnai modulation of rsv and therapeutic uses thereof: The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based...

20060166912 - Use of cytochrome p450 enzyme cyp2w1 as a drug target for cancer theraphy: The present invention relates to a novel drug target in cancer therapy. More closely it relates to use of the cytochrome P450 enzyme CYP2W1 and its promoter as a drug target for cancer therapy. It also relates to screening methods for obtaining therapeutic agents for cancer therapy and to therapeutic...

20060166925 - Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compou: The invention concerns novel substitution derivatives of N6-benzyladenosine having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells. This invention also relates to the methods of preparation of these N6-benzyladenosine derivatives and their use as drugs, cosmetic preparations and growth regulators comprising these derivatives as active compound...

20060166926 - Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases: The invention encompasses nucleoside compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions....

20060166927 - Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same: in which X is a divalent spacer group that is sufficiently long to allow the two oligosaccharide fragments A and B to each bind to one of the peptide sequences 125 to 143 of the C-terminal ends of a γ-interferon (γ-IFN) homodimer, n represents an integer from 0 to 10,...

20060166928 - Hyaluronic acid derivative gel and method for preparing the same: The present invention relates to a hyaluronic acid derivative gel, obtained by amidation of a hyaluronic acid, or its cationic salt, and an amine group-containing saccharide compound, having excellent viscoelastic properties, and a method for preparing it. Especially, the hyaluronic acid derivative gel according to the present invention shows responses...

20060166930 - Medicinal composition for ophthal use containing acetylated hyaluronic acid: The present invention provides an ophthalmic pharmaceutical composition containing acetylated hyaluronic acid and a pharmacologically acceptable carrier. Preferably, the average molecular weight of the acetylated hyaluronic acid is 10,000 to 1,000,000, and the acetyl group substitution number is from 2.0 to 4.0. In a preferred embodiment, this ophthalmic pharmaceutical composition...

20060166929 - Sugar-chain asparagine derivatives and processes for the preparation thereof: an asparagine-linked oligosaccharide derivative containing at least one fucose in N-acetylglucosamine on the nonreducing terminal side of an asparagine-linked oligosaccharide wherein the amino group of asparagine is modified with a biotin group or FITC group, a microplate having immobilized thereto a biotinated asparagine-linked oligosaccharide, and an affinity column having immobilized...

20060166931 - Clathrates of butylphtualide with cyclodextrin or its derivatives, a process for their preparation and the use thereof: The present invention relates to the inclusion complexes of butylphthalide, which is D,L-mixed or levorotatory, with cyclodextrin or cyclodextrin derivatives, to a process for their preparation and the use thereof. In the invention, the butylphthalide is complexed with cyclodextrin or cyclodextrin derivatives, preferably with hydroxypropyl-β-cyclodextrin, in order to increase the...

20060166932 - Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione: Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second...

20060166933 - Novel 2h-chromene derivatives as selective estrogen receptor modulators: The present invention is directed to novel 2H-chromene derivatives, pharmaceutical compositions containing them, their use in the treatment of disorders mediated by one or more estrogen receptors and processes for their preparation....

20060166934 - Composition comprising phytosphingosine derivatives for apoptosis induction: The present invention is related to compositions for the induction of apoptosis containing phytosphingosine derivatives as effective components. The present invention is related to compositions for the induction of apoptosis containing Vit D3 or calcipotriol as an effective component in addition to phytosphingosine derivatives. The compositions of the present invention...

20060166935 - Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction: This invention relates to the use of a fatty acid composition comprising at least (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA), or derivatives thereof, and (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA), or derivatives thereof for manufacturing of a medicinal product or a food stuff for the treatment and/or prevention of amyloidos-related diseases, such as Alzheimer's...

20060166936 - Diaminotriazole compounds useful as inhibitors of protein kinases: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders....

20060166937 - Bisphosphonates for the treatment of atherosclerosis and device comprising them: A method for the treatment of atherosclerosis, in particular atherosclerotic/valve calcification and plaque rupture/stroke, in a patient in need of such treatment, e.g. a patient with aterial or valve calcification, which comprises administering an effective amount of a bisphosphonate, e.g. zoledronic acid or salts or hydrates thereof, to the patient....

20060166938 - Method of treatment using bisphosphonic acid: The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficacious daily dose of a bisphosphonic acid or a pharmaceutically...

20060166939 - Fertilizer-compatible composition: This invention relates to pesticidal compositions compatible with liquid fertilizers and methods of use thereof....

20060166940 - Amino-propanol derivatives: i

20060166941 - Treatment and/or prevention of non-viral epithelial damage: There is provided the use of an inhibitor of phosphate transporter activity for the manufacture of a medicament for the prevention and/or treatment of non-viral damage to an epithelium, or of a condition caused or characterised by such damage. The inhibitor of phosphate transporter activity may optionally be a phosphono-carboxylic...

20060166942 - Combretastatin a-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4....

20060166943 - Microbicidal pyrimidine or triazine for preventing sexual hiv transmission: A present invention concerns the microbicidal activity of certain pyrimidine or triazine containing non-nucleoside reverse transcriptase inhibitors. The compounds of the present invention inhibit the systemic infection of a human being with HIV, in particular, the present compounds prevent sexual HIV transmission in humans....

20060166944 - 4-aminotetracyclines and methods of use thereof: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression....

20060166946 - Methods of preparing substituted tetracyclines with transition metal-based chemistries: The present invention relates to novel chemistries which allow for heretofore unobtainable substituted tetracycline compounds which exhibit significant antibacterial activity. The methods disclosed herein utilize reactive tetracycline-based precursor compounds, reactive organic substituent precursors and transition metal catalysts under conditions such that a tetracycline compound substituted with the desired organic substituent...

20060166945 - Substituted tetracycline compounds: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression....

20060166947 - Multiple myeloma treatments: Provided herein are methods for treating refractory or resistant multiple myeloma in a subject using indole derivatives....

20060166948 - Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries: Vitamin K is effective in counteracting the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin K can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular hypertrophy, congestive (right sided)...

20060166949 - Vitamin d analogues, compositions comprising said analogues and their use: t

20060166951 - Compositions and methods for sterol isolation and purification: Compositions and methods for isolating and purifying sterols, stanols, policosanols, and other organic molecules of interest are disclosed. The compositions encompass purified sterols comprising, for example, policosanols. Methods comprise solvent extraction of sterols from any solute comprising sterol-containing material. Such sterol-containing material may be in the form of plant material...

20060166950 - Treatment of neovascularization disorders with squalamine: Aminosterol compounds are described that are useful as inhibitors of the sodium/proton exchanger (NHE). Methods of using such aminosterols compounds are also enclosed, including those employing compounds that are inhibitors of a spectrum of NHEs as well as those using compounds that are inhibitors of only one specific NHE. Advantageous...

20060166952 - 2\"oxo-voruscharin and derivatives thereof: 2″oxo-voruscharin compound and derivatives thereof are disclosed as well as pharmaceutical compositions which include 2″oxo-voruscharin compound or derivatives thereof. The disclosed 2″oxo-voruscharin compound and its derivatives are useful for cancer treatment. Methods of treating cancer using the disclosed compounds are also disclosed....

20060166953 - Ciclesonide-containing sterile aqueous suspension: The present invention provides a ciclesonide-containing sterile aqueous suspension sterilized by autoclaving, wherein the concentration of ciclesonide after autoclaving is 95% or more compared to that before autoclaving, as well as methods of manufacturing a ciclesonide-containing sterile aqueous suspension comprising the step of sterilization by autoclaving a ciclesonide-containing aqueous suspension....

20060166954 - Polymorphis of a known thiophenecarboxylic acid dodecahydrocyclopenta (a) phenanthrenyl ester: Polymorphic crystal forms of 3-methylthiophene-2-carboxylic acid (6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl ester. The crystal forms possess anti-inflammatory activity and have very good stability. Methods for preparing the crystal forms are also described....

20060166955 - Production process for 16-dehydropregnenoneol and its analogs: The present invention relates to a clean process for the degradation of steroidal sapogenin to produce 16-dehydropregnenolone and its analogs. The pure or the crude pseudo steroidal sapogenin, derived from steroidal sapogenin, dissolved in organic solvent, reacts with hydrogen peroxide with or without metal compound and acid as catalyst, and...

20060166956 - Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration: The present invention is directed to the use of anercortave acetate or the alcohol thereof for the protection of visual acuity in patients with age related macular degeneration....

20060166957 - Methods of treating obesity and related disorders using tellurium selenium compounds: The present invention relates to methods of using tellurium and selenium containing compounds, and particularly to the use of small organic molecules containing tellurium or selenium as exemplified by the compound ammonium-trichloro(dioxoethylene-O,O′)tellurate (known by the abbreviation AS101) for treating obesity and obesity related disorders or complications and for reducing of...

20060166958 - Crystalline amoxicillin trihydrate powder: The invention relates to crystalline amoxicillin trihydrate powder having a bulk density higher than 0.45 g/ml. The invention also relates to a process for preparing crystalline amoxicillin trihydrate powder, said process comprising: crystallizing amoxicillin trihydrate from a solution containing dissolved amoxicillin; separating the crystals from said solution; and drying the...

20060166959 - Pharmaceutical compositions based on azetidine derivatives: e

20060166962 - N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines: It has now been found that certain novel N-(substituted aryl)-4-(disubstituted methyl)piperidine and pyridine derivatives have provided unexpected insecticidal activity. These compounds are represented by formula (I): wherein m, n, q, r, and s are independently selected from 0 or 1; and p is 0, 1, 2, or 3; A is...

20060166961 - Cell adhesion inhibitors:

20060166960 - Imidazole and benzimidazole derivatives useful as histamine h3 antagonists: and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I; also disclosed are methods of treating allergy, allergy-induced airway responses, congestion, obesity and metabolic syndrome using the compounds of Formula I, as well as combinations with other drugs useful...

20060166963 - Processes for producing 4-aminoquinazolines: d

20060166964 - Inhibitors of hcv replication: Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds....

20060166965 - Atypical antipsychotic agents having low affinity for the d2 receptor: d

20060166966 - 4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis: This invention relates to compounds of formula (I) which are cysteine protease inhibitors, in particular, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis....

20060166968 - Crystalline form of oxcarbazepine: Crystalline form F of oxcarbazepine....

20060166967 - Use of r-10-hydroxy-10,11-dihydro-carbamazepine in neuropathic pain: The present invention relates to the use of a mixture of the enantiomers of a compound of Formula (I) or of pharmaceutically acceptable salts of said enantiomers consisting of at least 55% of the R-enantiomer, most preferably of at least 98% of the R-enantiomer, and not more than 45 %...

20060166969 - Ampa antagonists for the treatment of dizziness, including vertigo and meniere's disorder: e

20060166971 - Benzamide derivatives as oxytocin agonists and vasopressin antagonists: Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or V1a receptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea....

20060166970 - Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation: The invention refers to the use of Reverse Transcriptase (RT) inhibitor compounds for the preparation of pharmaceutical compositions to counteract the loss of cellular differentiation in tumour and non tumour pathologies, said compound being able to bind the hydrophobic pocket on the RT subunit p66. Particularly preferred for such uses...

20060166972 - Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator: An mGluR4 receptor positive allosteric modulator is useful, alone or in combination with a neuroleptic agent, for treating or preventing movement disorders such as Parkinson's disease, dyskinesia, tardive dyskinesia, drug-induced parkinsonism, postencephalitic parkinsonism, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, parkinsonian-ALS dementia complex, basal ganglia calcification, akinesia, akinetic-rigid syndrome,...

20060166974 - Azabenzoxazoles for the treatment of cns disorders: The present invention relates to α7 nicotinic receptor agonists of formula I as described herein and to a method for treating disorders of the Central Nervous System (CNS) such as cognitive deficits in schizophrenia, by administering to a mammal an α7 nicotinic receptor agonist of formula I as shown herein....

20060166976 - Compositions and methods for treating or preventing convulsions or seizures: The present invention relates to compositions comprising S-tofisopam substantially free of R-tofisopam, and methods for treating or preventing convulsions and/or seizures comprising administration of the composition to subjects in need of treatment therefore. Also provided are compositions and methods for treating or preventing convulsions and/or seizures comprising administering S-tofisopam substantially...

20060166975 - Compositions and methods relating to novel compounds and targets thereof: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and related compounds and methods of using benzodiazepine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation...

20060166973 - Organic compounds as agents for the treatment of aldosterone mediated conditions: provide pharmacological agents which are inhibitors of the P450 enzyme, aldosterone synthase, and thus may be employed for the treatment of aldosterone mediated conditions. Accordingly, the compounds of formula I may be employed for prevention, delay of progression, or treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular,...

20060166977 - Antibacterial agents: Quinoline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans....

20060166978 - Substituted beta carbolines: i

20060166979 - New oxabispidine compounds useful in the treatment of cardiac arrhythmias:

20060166980 - New oxabispidine compounds useful in the treatment of cardiac arrhythmias:

20060166981 - Novel compounds for use in weight loss and appetite suppression in humans: Phenolic compounds with a phenolic molecule to which are covalently linked an oxygen-containing group, a nitrogen or another oxygen containing group, and a C1-C4 alkoxy group, obtainable from monocotyledonous plants, or by chemical synthesis, have been found to act as weight loss agents, appetite suppressants, mood enhancers and adjunctive therapy...

20060166984 - Amino substituted benzo(hetero)cyclic derivatives: Use of compounds Formula (I), A=a 5- to 7-membered ring which may contain 1-3 heteroatoms and which may be saturated or partially or completely unsaturated; R1═OH, SH, NH2, CN, NO2, halogen, C1-C6-alkyl, C1-C6-haloalkyl; C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C6-alkylthio, C1-C6-haloalkylthio, C2-C6-alkenyl, C2-C6alkenyloxy, C2-C6-alkenylthio, C2-C6-alkynyl, C2-C6-alkynyloxy, C2-C6-alkynylthio, C1-C6-alkylsulfonyl, C1-C6-alkylsulfoxyl, C2-C6-alkenylsulfonyl, C2-C6-alkylsulfoxyl, C1-C6-alkylcarbonyl, C1-C6-alkoxycarbonyl, C1-C6-aklylcarbonyloxy;...

20060166983 - Indole derivatives as ppar modulators: The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in (I) are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are...

20060166982 - Isotopically labelly indlinone derivatives and process for their preparation: Compounds which are isotopically labeled carbonium 14 [14C] indolinone derivatives and process for their preparation are disclosed; these compounds are useful for absorption, distribution, metabolism and excretion (ADME) studies....

20060166985 - Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa: The invention relates to novel chemical compounds, pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical compositions containing them, and to their use in medicine, particularly use in the amelioration of a clinical condition for which a thrombin inhibitor is indicated....

20060166988 - Novel compounds: The present invention is directed to novel compounds of Formula (I) for use in the treatment of diseases in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred....

20060166986 - Novel stereoselective synthesis of benzimidazole sulfoxides: The present invention relates to a process for stereoselective synthesis of substituted sulfoxides either as a single enantiomer or in an enantiomerically enriched form. Thus, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazol is reacted with (R)-camphorsulfonyl chloride to form a mixture of 1-(R)-camphorsulfonyl-5-(and 6-)methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylthio]-1H-benzimidazole, oxidized to obtain a diastereomeric excess of 1-(R)-camphorsulfonyl-(5- and 6-)-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(S)-sulfinyl]-1H-benzimidazole over 1-(R)-camphorsulfonyl-(5-...

20060166987 - Opioid receptor antagonists: A compound of the formula I: (I) wherein the variables are as described herein, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixture thereof, formulations and methods of use thereof are disclosed....

20060166989 - 2-naphthamide derivatives: The present invention relates to 2-naphthamides, which are useful as an active ingredient of pharmaceutical preparations. The 2-naphthamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor activity. Such diseases include urological diseases or disorder...

20060166990 - Novel aminobenzophenone compounds: The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer....

20060166991 - Pyridine carboxamide derivatives and their use as pesticides: e

20060166992 - Heterocyclically substituted imidazotriazines: The invention relates to new heterocyclically substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia....

20060166993 - Substituted imidazotriazines: The invention relates to new substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia....

20060166994 - Method for treating renal failure: Levosimendan or its active metabolite (II), which have been previously suggested for the treatment of congestive heart failure, are useful in the treatment of renal failure....

20060166997 - Phenylglycinamide derivatives useful as anticoagulants: The present invention relates generally to phenylglycinamide derivatives that inhibit serine proteases. In particular it is directed to novel phenylglycinamide derivatives, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or...

20060166996 - Phthalazine derivatives as phosphodiesterase 4 inhibitors: Compounds of formula I wherein R and R1 are as defined in the description. The compounds of formula I are PDE 4 inhibitors....

20060166995 - Piperidine-n-oxide-derivatives: m

20060166998 - Pyrrolo[1,2-b]pyridazine compounds and their uses:

20060166999 - Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl): The invention relates to the use of inhibitors of the microsomal triglyceride transfer protein (MTP) for reducing the number of postprandial triglyceride-rich lipoprotein particles (ppTRL) or for reducing their decomposition products i.e. the cholesterol-rich ‘small remnant particle’ (remnants). Said particles are associated with apolipoprotein B-48 (ApoB-48) and are designated as...

20060167000 - Neurologically-active compounds: The present invention relates to neurologically-active compounds, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of neurological conditions, more specifically neurodegenerative conditions such as Alzheimer's disease....

20060167001 - Pyridazinone-derivatives as pde4 inhibitors: e

20060167002 - Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists: The present invention relates to 1-aza-bicycloalkyl derivatives of formula (I), wherein X is CH2 or a single bond; Y is a group of formula (II, III, IV) and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes...

20060167003 - Probucol derivatives: Probucol derivatives and pharmaceutical compositions containing the same to be employed in treatment or prophylaxis of diseases....

20060167004 - 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders: Compounds of general formula: wherein R1 and R2 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain....

20060167005 - New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno [2,3-d] pyrimidine: (4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine or a salt thereof has value in the treatment of fibromyalgia, obesity, weight gain and other conditions....

20060167006 - Method of treatment: A method of treating a warm-blooded animal suffering from pancreatic cancer which. comprises administering to said animal in need of such a treatment a dose, effective against said disease, of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof....

20060167007 - Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof: m

20060167008 - Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists: In view of their capability to antagonize the actions of neurokinins by blocking the neurokinin receptors, and in particular antagonizing the actions of substance P by blocking the NK1 receptor, the compounds according to the invention are useful as a medicine, in particular in the prophylactic and therapeutic treatment of...

20060167009 - Monocyclic substituted phenyl methanones:

20060167010 - Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds: the dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond. Most preferably, R3 and R4 are hydrogen, and each are involved in hydrogen bonds, and/or the dashed bond is a double bond, such that the chemical backbone of the...

20060167011 - Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof: The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof and a process for making thereof. The compounds have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention also provides intermediate compounds useful in the process, as well as final products...

20060167012 - Sulfonyl-substituted bicyclic compounds as modulators of ppar: Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed....

20060167013 - Inhibitors for excessive accumulation of sodium ion in cells: A medicament for suppressing intracellular excess accumulation of sodium ions and a medicament for therapeutic and/or preventive treatment of cardiac disorders resulting from cardiosurgery operations which comprises an aminobenzenesulfonic acid derivative represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof...

20060167014 - Piperazine compounds and medicinal use thereof: wherein R1 and R2 are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4 and R5 are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6 and R7 are each hydrogen, lower alkyl, lower alkyl substituted by halogen,...

20060167015 - Inhibitors of tyrosine kinases: wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy...

20060167016 - 2,5-disubstituted pyrimidine derivatives: The present invention relates to novel 2,5-disubstituted pyrimidine derivatives which stimulate soluble guanylate cyclase, to processes for the preparation thereof, and to the use thereof for producing medicaments, in particular medicaments for the treatment of central nervous system diseases....

20060167019 - Fungicidal mixtures based on a trizolopyrimidine derivative: e

20060167017 - Fungicidal triazolopyrimidines, method for the production thereof, use thereof for controlling harmful fungl, and agents containing said fungicadal triazolopyrimidines:

20060167018 - Synergistically acting herbicidal mixtures: A synergistic herbicidal mixture comprising A) picolinafen; or one of its environmentally compatible salts; and B) a synergistically effective amount of at least a triazolopyrimidine herbicide selected from the triazolopyrimidine sulfonanilides and penoxsulam; or one of its environmentally compatible salts or esters; and, if desired, C) at least a safener....

20060167021 - Inhibition of src for treatment of reperfusion injury related to revascularization: The present invention provides methods for treating, preventing, or reducing reperfusion injury or post-pump syndrome by administering an inhibitor of vascular endothelial growth factor-mediated vascular permeability....

20060167022 - Method of female sexual enhancement: A method of sexual enhancement in women includes the steps of identifying a woman requesting sexual enhancement, assuring that the woman's blood includes estradiol within a first predetermined range and testosterone within a second predetermined range, and thereafter administrating a drug selected from the group consisting of vardenafil hydrochloride and...

20060167020 - Pyrazolopyrimidines as kinase inhibitors: The present invention relates generally to inhibitors of the kinases and more particularly to novel pyrazolopyrimidine compounds....

20060167023 - Substituted phenyl methanones: e

20060167024 - Cancer combination therapy comprising azd2171 and zd1839: The present invention elates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,...

20060167025 - Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs: e

20060167027 - Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,...

20060167026 - Antipsychotic molecular-targeting epithelial growth factor receptor: The purpose of this invention is to provide an agent useful for prevention and/or treatment of psychosis, schizophrenia and cognitive impairments. To solve this problem, this invention provides epidermal growth factor receptor inhibitors as therapeutic agents for psychosis, schizophrenia and cognitive impairments....

20060167029 - Mglur1 antagonists as therapeutic agents: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1-R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and...

20060167028 - Nicotine in therapeutic angiogenesis and vasculogenesis: The present invention features methods for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial disease....

20060167030 - Sulfonamido-macrocycles and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof: e

20060167031 - Method of administrating an anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor: The present invention relates to a method for treating a cancer comprising orally administering a composition containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1:0.5 at a dose of 20 to 80 mg/m2/day in terms of FTD in 2 to 4 divided portions per to patients in...

20060167032 - Pharmaceutical composition and method for treating disorders of the central nervous system: Disorders of the ventral nervous system (CNS) are treated by the administration of a GABA analog such as gabapentin or pregablin, an NMDA receptor antagonist such as dextromethorphan or d-methodone and, optionally, another pharmacologically active substance, e.g., one which is effective for the treatment of a CNS disorder....

20060167033 - 7-imino derivatives of camptothecin having antitumor activity: s

20060167034 - Novel benzonaphthyridines:

20060167035 - Quinoline derivative, its use, production and pharmaceutical agents containing the latter:

20060167036 - Tyrosine kinase inhibitors: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts,...

20060167037 - Combinational radiotherapy and chemotherapy compositions and methods: This invention relates to combination therapies involving radiotherapy and chemotherapy. In particular the invention relates to the use of isoflavones or analogues thereof in combination with radiotherapy or chemotherapy in the treatment of cancer and related diseases and conditions. The invention also relates to compositions and agents useful for same...

20060167038 - Pyrrolopyridine derivative and use thereof: wherein Ring A represents an optionally substituted pyridine ring; X represents an electron-attracting group; Y represents an optionally substituted divalent C1-6 chain hydrocarbon group; R1 represents an optionally substituted hydrocarbon group; and R2 and R3 each independently represents hydrogen, an optionally substituted hydrocarbon group or an optionally-substituted heterocyclic group, or...

20060167039 - Nicotinic alpha-7 receptor ligands and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds which act as ligands for the α7...

20060167041 - Imidazopyridine compound: wherein R1 represents a C1-C6 alkyl group or C2-C6 alkynyl group which may be substituted, or a phenyl group which may be substituted, R2 represents a hydrogen atom or a C1-C6 alkyl group, R3 represents methyl or ethyl group, R4 represents a C1-C6 alkyl group, R5 represents a hydrogen atom,...

20060167040 - Pyrazolopyridine derivates: New compounds of formula (I) and the salts, solvates and prodrugs thereof, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors....

20060167042 - Quinuclidine amide derivatives: New quinuclidine amide derivatives having the chemical structure of general formula (I) and pharmaceutically acceptable salts thereof including quaternary salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions 10 comprising them and their use in therapy as antagonists of M3 muscarinic receptors....

20060167043 - Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same: w

20060167044 - Piperidine derivatives and their use as anti-inflammatory agents:

20060167045 - Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist: The present invention relates to the treatment of hypertension and type 2 diabetes, Metabolic Syndrome or a pre-diabetic state, by the administration of a therapeutically effective amount of a combination of a dual PPARα/γ agonist and an Angiotensin II type I receptor antagonist, including pharmaceutically acceptable salts and solvates of...

20060167046 - Histamine h3 receptor antagonists, preparation and therapeutic uses: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-II3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods or using them to treat...

20060167047 - Tetrahydorquinoline derivatives and their use as fsh receptor modulators: The present invention relates to tetrahydroquinoline derivatives having general formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are H, Me; R3 is (2-6C)heterocycloalkyl(1-4C)alkyl, (2-5C)heteroaryl(1-4C)alkyl, (6C)aryl (1-4C)alkyl, (1-4C)(di)alkylaminocarbonylamino(2-4C)alkyl, (2-6C) heterocycloalkylcarbonylamino(2-4C)alkyl, R5-(2-4C)alkyl or R5-carbonyl(1-4C)alkyl; R4 is (2-5C)heteroaryl, (6C)aryl, (3-8C)cycloalkyl, (2-6C)heterocycloalkyl or (1-6C) alkyl and R5 is (di)(1-4C)alkylamino, (1-4C)alkoxy,...

20060167048 - N-4-piperidinyl compounds as ccr5 modulators: The invention provides a compound of formula (I): [Chemical formula should be inserted here. Please see paper copy.] wherein R1, R2, R3, R3a, R4, R4a, R5, and R6 are as defined; or a pharmaceutically acceptable salt thereof or a solvate thereof; compositions containing these compounds, processes for preparing them and...

20060167050 - Combined use of methylphenidate and melatonin for treating attention-deficit hyperactive disorder: The present invention relates to the combined use of methyl phenidate and at least one of melatonin, a melatonin analogue, or a pharmaceutically acceptable salt thereof in the treatment of attention deficit hyperactive disorder (ADHD). Methylphenidate and melatonin or its analogue may be used together or in combination with one...

20060167049 - Terphenly derivatives, preparation thereof, compositions containing same: e

20060167051 - Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride: The present invention relates to crystalline non-solvated 1-(4-2-piperidinylethoxy)phenoxy)-2-(4-methane-sulfonylphenyl)-6-hydroxynaphthalene hydrochloride, useful as a selective estrogen receptor modulator....

20060167053 - Heteroarylcarbamoylbenzene derivative: e

20060167052 - Piperidine derivative, process for producing the same, and use: wherein Ar is an aryl group, an aralkyl group or an aromatic heterocyclic group, each of which may be substituted, R1 is a hydrogen atom, an optionally substituted hydrocarbon group, an acyl group or an optionally substituted heterocyclic group, X is an oxygen atom or an optionally lo substituted imino...

20060167054 - Immunomodulation with novel pharmaceutical compositions: e

20060167055 - Non-nucleoside reverse transcriptase inhibitors: A compound of the formula (Y): where; R1 is O, S; R2 is a nitrogen-containing heterocycle; R3 is H, C1-C3 alkyl; X is —(C8R8)n-D-(C8C8′)m—; D is a bond, —NR9—, —O—, —S—, —S(═O)— or —S(═O)2; n and m are independently 0, 1 or 2, R8 and R8′ are independently H, C1-C3...

20060167057 - Compounds for the treatment of cns and amyloid associated diseases: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing CNS and amyloid associated disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, monitoring and treating or preventing CNS and amyloid associated disease....

20060167056 - Polymorphs of {5-[3-(4,6-difluoro-1h-benzoimidazol-2-yl)-1h-indazol-5-yl)-4-methyl-pyridin-3-ylmethyl}-ethyl-amine: The present invention relates to novel polymorphic forms of of 3{5-[3-(4,6-Difluoro-1H-benzoimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a hyperproliferative disorder or a mammalian disease condition mediated by protein kinase activity....

20060167058 - Ppar-activating compound: wherein A represents an oxygen atom, a nitrogen atom, or a sulfur atom; R represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkyl-alkyl group, an aryl group, an aryl-alkyl group an aryl-oxy-alkyl group, a pyridyl-alkyl group, an alkoxycarbonyl-alkyl group, or a...

20060167059 - Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1): wherein: X is a chemical bond, —CH2— or —C(O)—; R1 is alkyl, cycloalkyl, —CH2-cycloalkyl, pyridinyl, —CH2-pyridinyl, phenyl or benzyl; R2 is H, alkyl, cycloalkyl, —CH2-cycloalkyl, or perfluoroalkyl; R3 is H, halo, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH2-cycloalkyl, —NH2, or —NO2; R4 is optionally substituted phenyl, benzyl, benzyloxy, pyridinyl, or —CH2-pyridinyl, or...

20060167062 - Enema preparation: e

20060167061 - Novel process to prepare pioglitazone via several novel intermediates: A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine....

20060167063 - Process for the manufacture of isradipine: The present invention relates to an improved method for the manufacture of Isradipine, 4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester. which, involves reacting 2,1,3-benzoxadiazole-4-carboxaldehyde with methyl acetoacetate in the presence of acetic acid and piperidine in diisopropyl ether. To obtain the product 2-acetyl-3-benzofurazan-4-yl-acrylic acid methyl ester which is then reacted with isopropyl-β-aminocrotonate...

20060167060 - Pyrazole and pyrrole carboxamide insecticides: This invention provides compounds of Formula (I), N-oxides and salts thereof wherein: A is O or S; B is a phenyl ring or a pyridine ring, each ring optionally substituted with 1 to 5 R; J is a pyrazole or a pyrrole heterocyclic ring system as defined herein; and; R1...

20060167064 - Pharmaceutical liquid composition containing pyridone derivative: A pharmaceutical liquid composition containing the Pirfenidone in a very high concentration of more or less 25% by weight can be obtained by dissolving the Pirfenidone in diethylene glycol monoethyl ether. Even when the liquid medicinal compositions are stored for a long period of time, the Pirfenidone will not be...

20060167066 - Pyrrolidine inhibitors of iap: p

20060167065 - Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease: The invention encompasses ureido substituted benzoic acid compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions....

20060167067 - Gm-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent: wherein each R independently represents a hydrogen atom, a lower alkyl group, an aryl group, an allyl group, an aralkyl group, a halogen atom, a hydroxyl group, an amino group, R′O—, R′(C═O)—, R′(C═O)O—, or R′O(C═O)—, wherein R′ is an alkyl group containing 1 to 5 carbon atoms, or a pharmaceutically...

20060167068 - Method of treating self-injurious behavior with glutamate modulating agents: Inventors have made the surprising discovery that glutamate modulating agents are useful for treating borderline personality disorder and self-injurious behavior. Methods of treating borderline personality and self-injurious behavior are provided herein by administering a glutamate modulating agent to a patient are included herein. The invention also includes combination methods of...

20060167069 - Pharmaceutical composition of metaxalone with enhanced oral bioavailability: The present invention provides a pharmaceutical composition comprising metaxalone and pharmaceutically acceptable excipients, characterized in that the pharmaceutical composition has enhanced oral bioavailability. The present invention also provides a pharmaceutical composition comprising metaxalone and pharmaceutically acceptable excipients, characterized in that the extent of absorption of metaxalone is independent of whether...

20060167070 - Triazole compounds that modulate hsp90 activity: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising...

20060167071 - Liquid pharmaceutical formulations of palonosetron: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments....

20060167072 - Liquid pharmaceutical formulations of palonosetron: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments....

20060167073 - Liquid pharmaceutical formulations of palonosetron: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments....

20060167074 - Methods and compositions for the treatment of psychiatric disorders: A method for the prevention, treatment, or inhibition of a psychiatric disorder, in particular schizophrenia, is described which comprises administering a COX-2 inhibitor or prodrug thereof to a subject. Moreover, a method for the prevention, treatment, or inhibition of a psychiatric disorder, in particular schizophrenia or depressive disorders, is disclosed...

20060167075 - Modulators of faah: Methods for inhibiting the activity of FAAH and methods for preventing and/or treating certain disorders, e.g., anxiety disorders, sleep disorders and weight disorders, by administering celecoxib, valdecoxib or certain structurally related compounds at a dosage that is sufficient to treat and/or prevent the disorder are described....

20060167076 - Acutumine and acutumine compounds synthesis and use: t

20060167077 - Process for preparation of carvedilol: The invention solves a new method of preparation of Carvedilol for pharmaceutical use. In the synthesis of Carvedilol a reaction of 4-(oxirane-2-ylmethoxy)-9H-arbazole (II) with 2-(2-methoxyphenoxy)ethylamine salts (IV) in the presence of a base, in an alcohol having the number of carbons C2 to C5 as a solvent, at an elevated...

20060167079 - Pyrrolidine -2-ones as factor xa inhibitors: e

20060167078 - Substituted benzodioxepins: Benzodioxepines of the formula (I) and physiologically tolerated salts and solvates thereof, in which R1, R2, R3, R4, A, B, a and b have the meanings indicated in claim 1, are ligands of the 5HT1A receptors and/or the 5HT4 receptors with simultaneously strong serotonin reuptake inhibition. They can be employed...

20060167080 - Wortmannin analogs and methods of using same: Novel Wortmannin analogs and their use in inhibiting inhibiting PI-3-kinase activity in mammals as well as tumor formation in a subject are described herein....

20060167081 - Ep4 receptor agonists: This invention relates to potent selective agonists of the EP, subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of...

20060167082 - Nitrate esters of phenylaminothiophenacetic acid derivatives: i

20060167084 - Delta-9-thc compositions and methods for treating symptoms associated with multiple sclerosis: Methods are provided for, inter alia, treating and/or preventing symptoms associated with multiple sclerosis and MS relapse....

20060167083 - Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures: Methods for the treatment of diseases associated with aberrant cell survival, aberrant cell proliferation, abnormal cell migration, abnormal angiogenesis, abnormal estrogen/androgen balance, dysfunctional or abnormal steroid genesis, degeneration including degenerative changes within blood vessel walls, inflammation, or immunological imbalances utilising isoflav-3-ene and isoflavan compounds of the general formula (II) are...

20060167085 - Active substance combinations having insecticidal and acaricidal properties: The invention relates to novel active compound combinations of certain cyclic ketoenols and certain active compounds that together have unexpectedly good insecticidal and acaricidal properties....

20060167086 - Medicinal composition: (−)-DHM2EQ, which is useful as an antitumor agent and an anti-inflammatory agent, can be directly obtained by optically resolving (±)-DHM2EQ using an optically active column packed with an optical resolving agent containing, for example, amylose tris(3,5-dimethylphenylcarbamate) as an active ingredient. The (−)-DHM2EQ obtained by optical resolution using the optically active...

20060167087 - Substituted aniline derivatives: The present invention relates to aniline derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use....

20060167088 - Methods and compositions for treating ophthalmic conditions with retinyl derivatives: Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or...

20060167089 - Method for inhibition or treatment of colon tumorigenesis: A method is provided for inhibiting the development of colon tumorigenesis in a mammal by administering to the mammal a pharmacologically effective amount of an isothiocyanate selected from the group consisting of sulforaphane and phenethyl isothiocyanate....

20060167090 - Btk inhibitors: The invention provides BTK inhibitors, methods for their identification and use, and pharmaceutical compositions comprising BTK inhibitors, including allergy treatments....

20060167091 - Acaricide: wherein R1 is —C(O)ZR2; R2 is a C1-6 alkyl, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, (C1-6 alkoxy)C1-4 alkyl, (C1-4 alkylthio)C1-4 alkyl, or benzyl group; Z is an oxygen or sulfur atom; X and Y independently represent a halogen atom or a C1-6 alkyl or C1-4 haloalkyl group; m and n...

20060167092 - Lipophilic diesters of chelating agent for inhibition of enzyme activity: The present invention relates to the use of lipophilic diesters of the chelating agent 1,2-bis(2 aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA) for inhibition of proteolytic activities of certain metalloproteinases and of calpain. The invention further relates to methods for preventing, treating or managing MMP-related and calpain-related diseases or disorders in mammals comprising administering...

20060167093 - 3,4,5-trimethoxy phenyl-based ester compound and preparation method thereof and whitening cosmetic composition containing the same: The present invention relates to ester compounds derived from 3,4,5-trimethoxy phenyl acetate, 3,4,5-trimethoxy cinnamate or 3,4,5-trimethoxy hydrocinnamate that are represented by Formula (I), wherein R1 is CH2—, —CH═CH— or CH2—CH2, R2 is thymyl or carvacryl, to methods for preparing them, and to a whitening cosmetic composition containing the ester compounds....

20060167094 - Satiety agent: A composition and method for the control of appetite, having as an active ingredient a satiety agent and a pharmaceutically acceptable delivery agent, formulated so that the release of the active ingredient is predominately in the stomach....

20060167095 - Method for treating amyloidosis: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such...

20060167096 - Livestock products with an increased ppar/rxr heterodimer activator level: In the non-therapeutic method livestock animals, used in agri- or aquaculture for producing livestock products, are made to ingest at least one product comprising a PPAR/RXR heterodimer activator and/or a precursor thereof over such a period of time and in such an amount that the PPAR/RXR heterodimer activator is accumulated...

20060167097 - Compositions and uses of amooranin compounds: Amooranin (AMR) has been found to cause tumor cell death through G2/m cell cycle arrest, caspase activation, and apoptosis. Furthermore, it has been demonstrated that AMR is a substrate for P-glycoprotein. Based on these activities, AMR compounds can be used in the treatment of a number of diseases in which...

20060167098 - Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol: The present invention concerns a method for the treatment and/or the prevention of diseases linked to the accumulation of triglycerides in tissues and blood comprising at least the step of administering to a human or non human animal in need thereof, as therapeutically active agent, an effective amount of (3-aminoisobutyric...

20060167099 - Use of compositions that increase glutamate receptor activity in treatment of brain injury: The present invention provides a method for treating a brain injury. This method comprises administering to a mammal afflicted with a brain injury a pharmaceutical composition therapeutically effective to increase glutamate receptor activity in the brain of said mammal. The pharmaceutical composition is to be administered after an acute postinjury...

20060167100 - Orodispersible pharmaceutical composition of an antithrombotic compound: The invention relates to a solid orodispersible pharmaceutical composition of an antithrombotic compound (compound A), characterised in that it comprises compound A or a pharmaceutically acceptable salt thereof and granules consisting of co-dried lactose and starch....

20060167101 - Therapeutic use of d-methionine to reduce the toxicity of noise: Methods of preventing or reducing hearing or balance loss and damage to ear cells in patients who have been exposed to toxic levels of noise are provided. These methods comprise administering an effective amount of a methionine protective agent, such as D-methionine, prior to, simultaneously with, or subsequently to exposure...

20060167102 - Compositions comprising cyclopentane derivatives and their use: R2 is a radical chosen from linear, branched and cyclic hydrocarbon radicals comprising at least one unsaturation and comprising from 2 to 18 carbon atoms, which are optionally substituted by from 1 to 5 identical or different entities chosen from —OR′″, —OCOR′″, —SR′″, —SCOR′″, NR′″R″″, —NHCOR′″, halogen atoms, —CN, —COOR′″...

20060167103 - Methods of treating cancer with hdac inhibitors: The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention...

20060167104 - Method for extracting a novel compound from the root of a plant of the pentadiplandraceae family and use of n,n'-dibenzylthiourea as a medicine: The invention concerns a method for extracting a biological antioxidant form a plant of the pentadiplandraceae family genus Pentadiplandra brazzeana, brazzeana variety. The analysis of said biological oxidant has shown that said molecule is N,N′-dibenzylthiourea. The extraction of synthesis of said molecule should be carried out without any contact with...

20060167105 - Ccr-3 receptor antagonists: e

20060167106 - Compounds acting at the centrosome: The present invention relates to compounds, and methods utilizing compounds, which exhibit one or more of the following properties: i) disrupts organization of an actin cytoskeleton of a cell; ii) disrupts organization of a microtubule network of a cell; iii) induces accumulation of tubulin at centrosomes but does not induce...

20060167107 - Modulators (inhibitors/ activators) of histone acetyltransferases: e

20060167108 - Neuroprotective benzoate and benzamide compounds: The invention provides a therapeutic method for treating at least one symptom of a neurological disorder or disease such as Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide and/or glutamate in mammalian cells is implicated and inhibition of the...

20060167112 - Methods and compositions for regulating memory consolidation: The present invention makes available methods and reagents for enhancing and/or restoring long-term memory function and performance....

20060167111 - Methods for treating an impairment in memory consolidation: Impairments in memory consolidation are treated with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound. The method can include determining memory consolidation before, during and/or after administering the amphetamine compound....

20060167110 - Methods for treating cerebrovascular disease by administering desmethylselegiline: The present disclosure is directed to methods for reducing the neuronal damage associated with cerebrovascular disease, such as stroke or cerebral edema, by administering R(−)-desmethylselegiline, S(+) desmethylselegiline, or a combination of the two. The cerebrovascular disease may be caused by ischemia or hypoxia....

20060167109 - Methods of reducing rhinovirus contagion and related compositions: The present invention relates to the use of pleconaril to reduce the contagion of rhinovirus virions shed from a host infected with a rhinovirus and thereby reduce disease transmission or re-infection....

20060167113 - Process for preparation of polymorphic form of sertraline hydrochloride: The invention discloses a process for preparation of sertraline salts particularly sertraline hydrochloride Form V by dissolving or suspending sertraline mandelate in a solvent, reducing the pH of the solution or the suspension and isolating salt of sertraline The invention also provides for a pharmaceutical composition comprising said sertraline salt...

20060167114 - Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of nmda receptors: NMDA receptor antagonists can be used in methods of treatment, for reducing the frequency of stereotypic behaviors in animals and for reducing the frequency of analogous compulsive behaviors in humans, for example, those that have been said to be a manifestation of, or related to, obsessive-compulsive disorder. Of particular interest...

20060167115 - Compositions for the preservation of timber: The present invention provides antifungal compositions based on Tetrabromobisphenol A (TBBA), its homologues and derivatives, that can be used to preserve wood. The invention provide a method for the preservation of wood against fungal attack, that employs the impregnation of wood with TBBA or its homologues and derivatives....

20060167116 - Solubilising polysaccharides substituted with dydrophilic and hydrophobic groups: This invention relates to novel carbohydrate polymers with hydrophobic and hydrophilic side-groups suitable for solubilising, for example, hydrophobic drugs. The chain length of the carbohydrate polymeric backbone, and the type and number of the hydrophobic and hydrophilic side-groups are specifically chosen to improve the solubility properties of the carbohydrate polymers....

20060167117 - Controlled release compositions: A composition for controlled release of an active material such as a fragrance, sunscreen, vitamin or biocide in a product such as a hair shampoo, shower gel, another personal product such as an antiperspirant or deodorant, a household cleaning product such as a laundry detergent, hard surface cleaner or polishes,...

20060160721 - Method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis: The present invention relates to a composition comprising a detergent that can alter the activity of a lipoprotein. Additional aspects include the composition comprising a phospholipid, and the use of the compositions to treat and/or prevent cardiovascular diseases....

20060160720 - Protein stabilization in solution: Provided are storage containers for proteinaceous pharmaceutical compositions which are characterized in, among other things, comprising (i) a wall portion, wherein an inner wall material thereof is selected from silica-coated glass, silicone-coated glass, polymers of non-cyclic olefins, cycloolefin polymers and cycloolefin/linear olefin copolymers and (ii) one or more closure portions...

20060160722 - Compositions and methods for the prevention and control of insulin-induced hypoglycemia: Pharmaceutical composition comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia....

20060160723 - Glycoproteins having lipid mobilising properties and therapeutic applications thereof: A biologically active lipid mobilising agent for use in therapy is disclosed which has the properties and characteristics of a Zn-α2-glycoprotein, or of a fragment thereof having an apparent molecular mass Mr greater than 6.0 kDa as determined by gel exclusion chromatography. Methods of isolation and purification from biological material...

20060160724 - Preserving a hemoglobin blood substitute with a transparent overwrap: The invention relates to a method for preserving the stability of a hemoglobin blood substitute comprising maintaining the hemoglobin blood substitute in an atmosphere substantially free of oxygen. The method for preserving the deoxygenated hemoglobin blood substitute comprises maintaining the deoxygenated blood substitute in an oxygen barrier film overwrap package,...

20060160725 - Lipid metabolism improving agent: The present invention relates to a protein/phospholipid or protein hydrolyzate/phospholipid complex containing 10 wt % or more of bound phospholipid, a lipid metabolism improving agent comprising the complex, and a functional food comprising the complex. The present invention provides a lipid metabolism improving agent and a functional food, containing the...

20060160726 - Cyclic agonists and antagonists of c5a receptors and g protein-coupled receptors: The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions....

20060160727 - 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection: e

20060160735 - Beta-peptoids with antimicrobial activity: The present invention relates to beta-peptoids with antimicrobial activity. The present invention also relates to methods of producing β-peptoids. The antimicrobial β-peptoids of the invention are useful in pharmaceutical, healthcare, medical device, industrial, food, agricultural, and personal care applications....

20060160732 - Compositions and methods for inhibiting cell senescence and hyperproliferative disorders: The present disclosure provides compositions and methods for inhibiting cell and/or organismic senescence by treating conditions associated with aging and preventing undesirable cell proliferation. Compositions provided in the present disclosure include a transport agent attached to a therapeutic agent portion, wherein the transport agent portion has a role in transporting...

20060160733 - Compositions and methods for treating and preventing heart tissue degeneration and uses thereof: The present invention provides compositions useful for cardiac therapy comprising a cyclin-associated agent. The present invention also provides kits for use in delivering a cyclin-associated agent to cardiac cells in a subject, comprising the composition of the present invention and a catheter. The present invention additionally provides a methods for...

20060160728 - Diagnostic and therapeutic use of ensandin-0138 gene and protein for neurodegenerative diseases: The present invention discloses the differential expression of a gene coding for Ensadin-0138 in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject...

20060160741 - Dimeric tf antagonists: Dimer FVII polypeptides, which binds and inhibits two TF molecules simultaneously....

20060160739 - Grf-containing lyophilized pharmaceutical compositions: Human growth hormone factor (GFR) containing pharmaceutical compositions are described, and more precisely, lyophilized compositions of hGRF stabilized by means of saccharose....

20060160734 - In situ method for treatment and repair of meniscal injuries: A method for in situ repair of meniscal injuries comprising induction of meniscal repair and regeneration by introducing an adhesive collagen-polyethylene glycol (PEG) hydrogel to a site of injury alone, supplemented with a synovial tissue or in conjunction with a support matrix....

20060160729 - Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis: Methods and compositions for manipulating the directed navigation of physiological tracking tubular structures are provided. A novel cell-bound receptor, roundabout-4 (Robo-4), is described. The Robo-4 receptor shows sequence and structural similarity to members of the roundabout family of receptors. Also, the Robo-4 receptor binds Slit ligand, a known receptor of...

20060160737 - Methods of using il-1 antagonists to treat polymyalgia rheumatica and giant cell arteritis: Methods of treating, inhibiting, or ameliorating polymyalgia rheumatica (PMR) and/or giant cell arteritis (GCA) in an adult or juvenile human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein PMR and/or GCA are inhibited, or ameliorated. The IL-1...

20060160731 - Peptide nucleic acids: A novel class of compounds, known as peptide nucleic acids, bind complementary ssDNA and RNA strands more strongly than a corresponding DNA. The peptide nucleic acids generally comprise ligands such as naturally occurring DNA bases attached to a peptide backbone through a suitable linker....

20060160736 - Pharmaceutical compositions and methods for restoring beta-cell mass and function: Pharmaceutical compositions and methods for using are provided for restoring β-cell mass and function in a mammal in need thereof. The pharmaceutical compositions have a biological response modifier and a β-cell growth factor in admixture with a pharmaceutically acceptable carrier, adjuvant or vehicle....

20060160738 - Stem cell factor-like proteins and uses thereof: The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor SCFA2, SCFA4 or SCFA4v polynucleotides and polypeptides. The invention further relates to the therapeutic use of SCFA2, SCFA4 or SCFA4v to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa....

20060160730 - Target for angiogenesis and anti-angiogenesis therapy: The present disclosure concerns the use of peptides and compositions, such as pharmaceutical compositions, to influence angiogenesis. Particular methods are useful for promoting angiogenesis, while others are particularly useful for inhibiting angiogenesis....

20060160740 - Use of glp-1 or analogs in treatment of stroke: This invention provides a method of reducing mortality and morbidity associated with stroke. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose....

20060160742 - Neuropeptide-2 receptor (y-2r) agonists and uses thereof: i

20060160745 - Agents for preventing postoperative recurrence of premenopausal breast cancer: The agent for preventing the postoperative recurrence of premenopausal breast cancer comprising a GnRH agonist or antagonist of the present invention can prevent the postoperative recurrence of premenopausal breast cancer without severe side effects. In addition, by using the agent of the present invention in the form of a long...

20060160743 - Peptides that selectively home to heart vasculature and related conjugates and methods: The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a variety of cardiovascular diseases as described below....

20060160744 - Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder: The invention concerns the use of a bombesin/gastrin releasing peptide antagonist in the treatment of inflammatory and immune-mediated inflammatory conditions, in particular sepsis, acute lung injury and rheumatoid arthritis as well as for the treatment or prophylaxis of brain disorders, preferably bipolar disorder, and in particular the different forms and/or...

20060160746 - Amino acid and peptide conjugates of amiloride and methods of use thereof: The present invention provides compositions comprising amiloride amino acid and peptide conjugates. Efficient methods are also provided for administering the amiloride conjugates of the present invention for treating cancer or a central nervous system disease or disorder or for preventing or reducing ischemia-reperfusion injury. Further, kits are provided for the...

20060160748 - Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof: Disclosed are compounds containing single amino acids, peptides, or derivatives thereof which are selectively delivered to the mitochondria of a cell. Compounds of the invention exhibit antioxidant activity thereby reducing reactive oxygen species in cells. These compounds are useful for inhibiting oxidative stress-induced cell injury or death both in vivo...

20060160747 - Statine derivatives for the treatment of alzheimer's disease ii: s

20060160749 - Tripeptide and tetrapeptide thioethers: Tripeptide and tetrapeptide thioethers, pharmaceutical compositions containing them, their pharmaceutical use, and their preparation. The compounds are useful in potentiating the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exerting toxicity in tumor cells, elevating the production of GM progenitors in bone marrow, stimulating the differentiation of bone marrow,...

20060160751 - 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism: The present invention provides a method for increasing the efficacy of antifolates which act via inhibition of dihydrofolate reductase (DHFR). The method comprises the steps of administration of 5-amino-4-imidazolecarboxamide riboside (Z) or its base with the antifolate such that the targeted cells are exposed to both the antifolate and Z...

20060160750 - Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite...

20060160752 - Promoter for the production of hyaluronic acid containing ginsenoside compound k: There are provided a promoter containing ginsenoside compound K for the production of hyaluronic acid, and more particularly, a new efficacy of 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol (compound K), a chief metabolite of ginseng saponin, to increase the expression of hyaluronic acid synthase gene in human cell and thereby to promote the production of...

20060160753 - Micronutrient formulation for cognitive & mood benefits: A food product or dietary supplement is provided comprising (i) preferably at least 5 mg in total, of one or more isoflavones, (ii) preferably at least 0.1 mg, vitamin B6, and optionally (iii) preferably at least 1 mg, vitamin E. The food product or dietary supplement can be used to...

20060160754 - Glycyrrhizin high-concentration preparation: To provide a glycyrrhizin/aminoacetic acid/cysteine combination drug containing an active ingredient in high concentration and excelling in stability and safety. Stability at compounding of active ingredient in high concentration has been improved by avoiding the addition of sulfite salts having been used as a stabilizer in existing products. As glycyrrhizin...

20060160755 - Neoadjuvant treatment of breast cancer: Neoadjuvant treatment of inflammatory or T3 to T4 breast cancer is carried out by administering to such patients a number of cycles of chemotherapy treatment in which DPPE first is administered followed by a combination of anthracyclines and taxanes....

20060160756 - Treatment and prevention of multi-drug resistance: A method of preventing formation of multi-drug resistance (MDR) or of treating a patient that has developed or is subject to the development of MDR comprises administering a regimen comprising one or more active drugs together with one or more MDR inhibitors such that the pharmacokinetic (PK) profile of the...

20060160758 - Antisense modulation of cd40 ligand expression: Antisense compounds, compositions and methods are provided for modulating the expression of CD40 ligand. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40 ligand. Methods of using these compounds for modulation of CD40 ligand expression and for treatment of diseases associated with expression of CD40...

20060160759 - Influenza therapeutic: The present invention provides compositions comprising an RNAi-inducing entity targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for inhibiting a biological activity of an influenza virus and/or for treatment or prevention of influenza. The...

20060160764 - Limks as modifiers of p53 pathway and methods of use: Human LIMK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of LIMK are provided....

20060160762 - Methods for the treatment, diagnosis, and prognosis of cancer: We have discovered that antizyme inhibitor (AZI) is expressed at increased levels in highly proliferating cells. We have also discovered that inhibiting antizyme inhibitor, including inhibiting its expression, reduces the growth of cancer cells. The present invention is directed to the use of inhibitors of antizyme inhibitor for the treatment...

20060160760 - Modulation of glucocorticoid receptor expression: Compounds, compositions and methods are provided for modulating the expression of glucocorticoid receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucocorticoid receptor. Methods of using these compounds for modulation of glucocorticoid receptor expression and for diagnosis and treatment of diseases and conditions associated with expression of glucocorticoid receptor...

20060160761 - Regulation of vascular endothelium using bmx tyrosine kinase: Vascular endothelia are subject to atherosclerotic and arteriostenotic effects transduced by molecules, such as thrombin, IL-3 and VEGF which can lead to vessel occlusion or stenosis. An endothelial signaling pathway involving the Bmx tyrosine kinase contributes to normal endothelial nonthrombogenic, inflammatory and growth conditions of arterial vessels, and regulation of...

20060160757 - Rna interference mediated inhibition hairless of (hr) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating hairless (HR) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of hairless gene expression and/or activity...

20060160763 - System for delivering therapeutic agents into living cells and cells nuclei: A novel class of oligomeric compounds designed for forming conjugates with biologically active substances and delivering these substances to a desired bodily target are disclosed. Novel conjugates of these oligomeric compounds and biologically active moieties, pharmaceutical compositions containing such conjugates, and uses thereof as delivery systems for delivering the biologically...

20060160765 - Inhibitors of nucleoside phosphorylases and nucleosidases: The present invention relates to compounds of the general formula (I) which are inhibitors of purine muclioside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5′-methylthioadenosine phosphorylases (MTAP), 5′-methylthioadenosine mucliosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including...

20060160766 - Therapy-enhancing glucan: A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal, and at least one antibody for the cancer. A method of treating...

20060160767 - Method of providing food product with prolonged energy release: The subject of the present invention is a nutritive composition for prolonged release of energy, characterized in that it comprises between 50 and 99.9%, preferably 60 to 99.9% and still more preferably between 70 and 99.9% by weight of branched maltodextrins having between 15 and 35% of 1-6 glucoside linkages,...

20060160768 - Novel polysaccharides with antithrombotic activity comprising at least one covalent bond with biotin or a biotin derivative: The present invention relates to novel synthetic polysaccharides with antithrombotic activity exhibiting at least one covalent bond with biotin or a biotin derivative and to a process employing avidin or streptavidin which makes it possible to neutralize these polysaccharides....

20060160769 - 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses: This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as...

20060160770 - Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds: i

20060160771 - Aminophosphonic acid derivatives, addition salts thereof and sip receptor modulators:

20060160772 - Process for manufacture of fosinopril sodium: The present invention discloses a process for the synthesis of fosinopril as a single desired isomer of high purity in two steps comprising of (a) preparation of fosinopril as a mixture of four diastereomers and (b) separation of the desired isomer from the mixture through formation of alkali metal salts...

20060160773 - Combretastatin derivatives with cytotoxic action: e

20060160774 - Oxathiazaphospholidine free radical control agent: wherein R2 represents a moiety selected from the group consisting of alkyl groups, alkenyl groups, alkynyl groups, aryl groups, heteroaryl groups, and alkaryl groups; wherein the alky groups, alkenyl groups, alkynyl groups, aryl groups, heteroaryl groups, and alkaryl groups can be substituted, unsubstituted, linear, branched or cyclic; and wherein Ar...

20060160775 - Combination therapy: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,...

20060160776 - Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage: The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of...

20060160777 - New use of gababeta receptor agonists: The present invention relates to the use of GABAB receptor agonists for the treatment as well as the prevention of cough....

20060160778 - Fluorocombretastatin and derivatives thereof: obtained by total synthesis. The strategy developed for each of the compounds is to i) replace a halogen (i.e. fluorine atom) to hydrogen on olefinic bound; ii) replace an aromatic ring in a natural product with an amino-aromatic ring. Said compounds recognize and bind the tubulin site: are useful for...

20060160779 - 2,2-di-substituted 1alpha,25-dihydroxy-19-norvitamin d derivative: A novel 2,2-di-substituted 19-norvitamin D derivative. It is a compound represented by the general formula (I) wherein R1 and R2 are the same or different and each represents hydroxy and A represents hydrogen, or an unsubstituted linear or branched alkyl....

20060160780 - Nitrate esters of corticoid compounds and pharmaceutical applications thereof: n

20060160781 - Nitrate esters of corticoid compounds and pharmaceutical applications thereof:

20060160782 - 2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumour action: The invention relates to the use of 2-substituted estra-1,3,5(10)-triene-3-yl sulfamates of general formula I, in addition to their pharmaceutically acceptable salts for producing a medicament Said compounds have an anti-tumour action....

20060160784 - Method for treating neurologic diseases: Disclosed herein are texaphyrin-metal complexes, compositions comprising such complexes, pharmaceutical formulations comprising such complexes, and methods for treating neurologic diseases, disorders and conditions and or free-radical associated diseases, disorders and conditions using such complexes, compositions and pharmaceutical formulations....

20060160783 - Novel omeprazole forms and related methods: The invention provides: (1) novel sodium-containing omeprazole salts formed by the reaction of omeprazole and a sodium source in a crystallization solvent; (2) novel zinc-containing omeprazole salts formed by the reaction of omeprazole and a zinc source in a crystallization solvent, including salts formed by the recrystallization of a zinc...

20060160785 - Ezetimibe polymorphs: Provided are processes for preparing crystalline forms of ezetimibe, such as ezetimibe Form A or Form B, for example, by precipitating ezetimibe from selected solvents. Alternatively, some forms may be transformed into different forms at elevated temperatures or under various humidity conditions, or by micronization. Also provided are micronized ezetimibe...

20060160787 - Methods for preventing and treating cancer using n-thiolated beta-lactam compounds and analogs thereof: wherein R1is a hydrocarbon group having 1-8 carbon atoms; R3 is an organothio group; and R4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, cycloalkenyl, or heterocycloalkenyl, and analogs and pharmaceutically acceptable salts, esters and amides thereof. The subject invention also concerns methods for inducing tumor cell death or inhibiting...

20060160788 - Substituted phenyl methanone derivatives: R1, R2, R3, n, and m, are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. These compounds are good inhibitors of the glycine transporter 1 (GlyT-1) and are useful for the treatment of CNS disorders such as schizophrenia, cognitive impairment, and Alzheimer's disease....

20060160786 - Substituted triazole derivatives as oxytocin antagonists: The present invention relates to substituted triazoles of formula (I), uses thereof, processes for the preparation thereof and compositions containing said compounds. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction....

20060160789 - Use of pharmacological compounds for the prevention or treatment of acute tolerance to morphines: e

20060160790 - Thioureas as factor xa inhibitors: The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat...

20060160792 - Treatment of cancers with methylol-containing compounds and at least one electrolyte: A method of inhibiting growth of a tumor cell in a mammal may include steps of administering to the mammal a first solution including a tumor-inhibiting methylol-containing compound, the first solution further including a first combination having a plurality of physiologically acceptable electrolytes or a second combination having at least...

20060160791 - Wood preservative formulations: The invention provides a preservative composition comprising, in synergistic proportions, an oxathiazine compound plus one or more of a quaternary ammonium compound and a triazole compound as well as methods of treating wood and other material with said compositions....

20060160793 - Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions: The invention relates to a method of treatment or prevention of acute coronary syndrome or related conditions or reducing the risk of cardiovascular events comprising the administration of a therapeutically or prophylactically effective amount of meloxicam in combination with a therapeutically or prophylactically effective amount of an antiplatelet agent to...

20060160794 - Tachykinin receptor antagonists: The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins....

20060160796 - N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases: The present invention relates to certain compounds of Formula (I) which can be useful in the treatment of diseases, such as, cancer, metabolic disorders, Type 2 Diabetes, dyslipidemia and/or hyperchloesterolemia:...

20060160795 - Novel compounds for use in weight loss and appetite suppression in humans: Phenolic compounds with a phenolic molecule to which are covalently linked an oxygen-containing group, a nitrogen or another oxygen containing group, and a C1-C4 alkoxy group, obtainable from monocotyledonous plants, or by chemical synthesis, have been found to act as weight loss agents, appetite suppressants, mood enhancers and adjunctive therapy...

20060160797 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1: The present invention relates to using a compound having the formula (I) wherein T is I) thienyl, which optionally is substituted with halogen, or II) phenyl optionally substituted with halogen and/or C1-6-alkyl; E is a bond, —CH2— or —CO—; L is a bond, —CH2—, —CHR4— or —NR3—; R3 is H,...

20060160798 - Viral polymerase inhibitors: e

20060160799 - Transcription factor modulating compounds and methods of use thereof: Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compounds, as well as pharmaceutical preparations thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms....

20060160800 - Compositions and methods of treating cell proliferation disorders: The invention relates to compounds and methods for treating cell proliferation disorders....

20060160803 - Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity: The present invention provides novel cinnamide compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases....

20060160804 - Novel pyridazine derivatives and medicines containing the same as effective ingredients: wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (subsituted) aryl group, a (substituted) aryloxy group, a (substituted)...

20060160802 - Peptide deformylase inhibitors: Novel PDF inhibitors and novel methods for their use are provided....

20060160801 - Pyrimidinone derivaties as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes: The invention relates to novel heterocyclic derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases....

20060160805 - Thiotungstate analogues and uses thereof: The current invention provides novel thiotungstate derivatives, methods of making novel thiotungstate derivatives, pharmaceutical compositions of novel thiotungstate derivatives, methods of using novel thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders and obesity and methods of using pharmaceutical compositions of thiotungstate derivatives to treat diseases associated...

20060160808 - New carboxylic acid derivatives, their preparation and their use: e

20060160807 - Selective inhibitors of erk protein kinase and uses thereof: Described herein are compounds that are useful as ERK2 inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including proliferative disorders such as cancer....

20060160806 - Ureas having antiangiogenic activity: s

20060160809 - N-[(piperazinyl)hetaryl]arylsulfonamide compounds: with the radicals n, R1, R2, R3, R4 and R5 having the meanings given in the patent claims, to the N-oxides and to the physiologically tolerated acid addition salts of these compounds and to pharmaceutical compositions which comprise at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one of claims 1...

20060160810 - 2-alkoxyphenyl substituted imidazotriazinones: The 2-phenyl-substituted imidazotriazinones having short unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolising phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for treating cardiovascular and cerebrovascular disorders and/or disorders of the...

20060160811 - Aryl-condensed 3-arylpridine compounds and use thereof for controlling pathogenic fungi: R3 is hydrogen, C1-C6-alkyl, C1-C6-haloalkyl or C3-C6-cycloalkyl which is optionally mono- or polysubstituted by alkyl and/or halogen; and the agriculturally acceptable salts of compounds I, plant protection agents, containing at least one compound of general formula I and/or one agriculturally-acceptable salt of I and at least one liquid or solid...

20060160812 - Methods for treating neural disorders and conditions, and compounds useful therefor: In accordance with the present invention, there are provided novel compounds that protect neurons and/or promote neuroregeneration and/or promote memory formation. Such compounds are useful for treatment of a variety of neural disorders and conditions. In another aspect of the present invention, there are also provided formulations containing one or...

20060160814 - Phosphodiesterase 10 inhibitors:

20060160813 - Pyrrolidinedione substituted piperidine-phtalazones as pde4 inhibitors:

20060160816 - Pirazino(aza) indole derivatives:

20060160815 - Pyrrolo[1,2-a]quinoxalin-5-(4h)-yl)sulfonyls and carbonyls and their use as estrogenic agents:

20060160817 - Ion channel modulators and methods of use: In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels and/or calcium channels....

20060160818 - Ocular hypotensive agent: wherein A is methylene group, ethylene group or oxygen atom, n is an integer of 3 or 4, R is phenyl group optionally substituted, 2-pyridyl group optionally substituted or 2-pyrimidinyl group optionally substituted, and a solid line with a dotted line in the bicyclo ring means a single bond or...

20060160821 - Ureas as factor xa inhibitors: The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat...

20060160819 - Substitued piperazine carbamates: Novel piperazines, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which modulation of lipolysis, such as decreased lipolysis is beneficial....

20060160820 - Substituted piperazine carbamates: Novel substituted piperazine carbamates, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which modulation of the activity of hormone sensitive lipase...

20060160822 - Method of using flibanserin for neuroprotection: The present invention relates to the use of 1-[2-(4-(3-trifluoromethyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one, optionally in the form of its pharmaceutically acceptable acid addition salts and optionally in the form of its hydrates or solvates, for preparing a pharmaceutical composition with a neuroprotective activity....

20060160823 - Particulate-stabilized injectable pharmaceutical compositions of posaconazole: The present invention provides formulations useful for treating infections, in particular, formulations that include the active pharmaceutical ingredient Posaconazole in an injectable suspension of particles that is stable when subjected to terminal sterilization. Preferred median particle sizes of between 1.5 and 3.0 microns are found to result in superior pharmacokinetic...

20060160824 - Indole derivatives as serotonin reuptake inhibitors: Compounds of the formula (I), the use thereof for the preparation of a medicament for the treatment of diseases associated with the serotonin receptor and/or serotonin reuptake, in particular for the preparation of a medicament as anxiolytic, antidepressant, neuroleptic and/or antihypertonic and/or for positively influencing obsessive-compulsive disorder (OCD), sleeping disorders,...

20060160825 - Tetralin and indane derivatives and uses thereof: m

20060160826 - Methods of treating ischemic related conditions: The present invention relates to methods of treating ischemia-related conditions by administering to a patient in need of such methods certain thiosemicarbazone compounds. Preferred embodiments of the present invention relates to methods of treating specific ischemia-related conditions, including but not limited to Alzheimer's disease, Parkinson's disease, Coronary artery bypass graft...

20060160827 - Indolo[2,1-b] quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith: wherein A, B, C, D, E, F, G and H are independently selected from carbon and nitrogen, or A and B or C and D can be taken together to be nitrogen or sulfur, with the proviso that not more than three of A, B, C, D, E, F, G...

20060160828 - Amino-imidazolones for the inhibition of beta-secretase: e

20060160830 - 3,5-disubsitituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof: The invention is directed to 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and pharmaceutical compositions containing them, and to methods of treating diseases and disorders described herein, by administering effective...

20060160829 - Thienopyrimidine compounds and use thereof: wherein R1 is a C1-4 alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a hydroxy group, (3′) a C1-4 alkyl and (4′) a C1-4 alkoxy, (2) a phenyl which may have a...

20060160831 - Pyrrolopyrimidinone derivatives: A1 and A3 are a single bond, an aliphatic hydrocarbon group; A2 and A4 are a single bond, CO, COO, CONR, O, OCO, NR, NRCO, NRCOO, etc.; G1 is a single bond, an aliphatic hydrocarbon, aromatic hydrocarbon, heterocyclic; G2 is H, an aliphatic hydrocarbon, an alicyclic hydrocarbon, an aromatic hydrocarbon,...

20060160832 - Nitrogen-containing aromatic derivatives:

20060160833 - Plant protection agents: The present invention relates to a microbicide composition for plants, containing at least two active ingredient components in an amount producing synergistic activity, together with an appropriate filler, wherein component I is the compound 2-[α-{[(α-methyl-3-trifluoromethyl-benzyl)imino]-oxy}-o-tolyl]-glyoxylic acid-methylester-O-methyloxime, and component II is a compound selected from the group consisting of IIA) 5,7-dichloro-4-(4-fluorophenoxy)quinoline...

20060160834 - Combination therapy for the treatment of hypertension: The present invention relates to compositions comprising an anti-obesity agent and an anti-hypertensive agent useful for the treatment of hypertension, hypertension associated with obesity, and hypertension-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering...

20060160835 - Methods and compositions for treatment of central nervous system disorders: The invention provides methods of screening for substances having an effect on a nicotine receptor by contacting a cell having a nicotine receptor with a test substance; and determining any increase or decrease in phosphorylation of Janus-Activated Kinase 2 (JAK2). An increase in phosphorylation of JAK2 indicates that the test...

20060160836 - Estrogen receptor structure: Estrogen receptor ligands, estrogen receptor polypeptide/ligand complexes, crystals of estrogen receptor polypeptide/ligand complexes, and related methods and software systems are disclosed....

20060160838 - Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases: and diastereomers, tautomers, solvates, metabolites, and pharmaceutically acceptable salts thereof, wherein X, A, L and Y are as defined herein. Such compounds are useful in the treatment of immunoregulatory and respiratory diseases in mammals. Also disclosed are methods of using such compounds in the treatment of immunoregulatory and respiratory diseases...

20060160837 - Rapamycin compounds in the treatment of neurofibromatosis type 1: The present invention is directed to methods for treating neurofibromatosis type 1 (NF1) using rapamycin, derivatives of rapamycin or prodrugs of rapamycin. The invention covers the treatment both of non-malignant fibromas, as well as a variety of tumors associated with cells that have mutations in the NF1 gene....

20060160839 - Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors: e

20060160840 - Tetrahydroisoquinolines as factor xa inhibitors: The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat...

20060160841 - Crystallization via high-shear transformation: The invention relates to a process or apparatus for transforming a first polymorph of a chemical material into a second polymorph of the same chemical material, utilizing an apparatus comprising a vessel connected to a re-circulation system, the process comprising the steps of: suspending said first polymorph in a solution...

20060160842 - Heteroaryl fused aminoalkyl imidazole derivates: selective modulators of gabaa receptors: or the pharmaceutically acceptable non-toxic salts thereof wherein the A, B, C, D, X, R1, R2, R3, R4, R5, and R6, are variables defined herein, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain...

20060160843 - Method for treating neuropathic pain and associated syndromes: The present invention is directed to the use of ibudilast for treating neuropathic pain....

20060160845 - Aminophenyl derivatives as selective androgen receptor modulators: e

20060160844 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided....

20060160846 - Quinoline derivatives: s

20060160847 - 2,4-dihalogen-6-(c2-c3alkyl)-phenyl substituted tetramic acid derivatives: in which A, B, D, G, X, Y and Z are as defined in the disclosure, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides, and also to selective herbicidal compositions comprising the 2,4-dihalo-6-(C2-C3-alkyl)phenyl-substituted tetramic acid derivatives and a crop plant...

20060160848 - Method of controlling damage mediated by alpha, beta-unsaturated aldehydes: This invention relates to a method for inhibiting the reaction of an α,β-unsaturated aldehyde with a biological molecule, the method including the step of administering hydralazine and/or dihydralazine in an amount that is effective to reduce the rate of reaction of the α,β-unsaturated aldehyde with the biological molecule....

20060160849 - Pharmaceutical compositions containing sulphonic acid derivatives: A naphthalenesulfonic acid or quinolinesulfonic acid of formula (I), wherein A is N or a CR8 formula group, where R8 is H, OH, NR10R11, independently from one another, where R10 and R11 represent H or C1-C6 alkyl or a group of formula NH—CO—R12, where R12 is C1-C6 alkyl or C6-C10...

20060160850 - Bicyclic heterocycles as cannabinoid receptor modulators: n

20060160851 - Substituted piperidine carbamates: Novel substituted piperidine carbamates, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which modulation of the activity of hormone sensitive lipase...

20060160852 - Composition containing anti-dementia drug: An object of the present invention is to provide, for the case of implementing a therapeutic method in which at least two kinds of anti-dementia drugs are used together, a composition that has a good therapeutic effect on the dementia, and also gives excellent compliance. Another object of the present...

20060160853 - 2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists: 2-[(4-Benzyl)-1-piperidinyl)-methyl]benzimidazole-5-ol derivatives are NMDA NR2B receptor antagonists useful in the treatment of pain and other NMDA mediated diseases....

20060160855 - 5-aminoindole derivatives as h3 inverse agonists: wherein R1, R2, R3, R4 and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with...

20060160854 - Methods for the treatment of cachexia: Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNFα in a mammal....

20060160856 - Diarylurea derivatives and their use as chloride channel blockers: The present invention relates to novel diarylurea derivatives useful as chloride channel blockers. In other aspects the invention relates to the use of these compounds in a method for therapy, such as for the treatment of bone metabolic diseases, diseases responsive to modulation of the mast cell or basophil activity,...

20060160857 - Thiazole-4-carboxyamide derivatives: e

20060160858 - Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use: Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or...

20060160859 - Method for treating hiv infection through co-administration of tipranavir and gw873140: A method for treating HIV infection through co-administration of tipranavir and GW873140....

20060160862 - Caspase inhibitors and uses thereof: m

20060160861 - Novel nicotinamide pyridinureas as vascular endothelial growth factor (vegf) receptor kinase inhibitors: The invention relates to novel nicotinamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis....

20060160863 - Polymorphic and amorphous forms of 2-{3-[(e)-2-(4,6-dimethyl-pyridin-2-yl)-vinyl]-1h-indazol-6-ylamino}-n-(4-hydroxy-but-2-ynyl)benzamide: e

20060160860 - Synthesis of polyamine compounds:

20060160864 - Acrylamide derivative, process for producing the same, and use:

20060160865 - Pyridinyl carbamates: Novel substituted pyridinyl carbamates, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which modulation of the activity of hormone sensitive lipase...

20060160866 - Anti-coronavirus compounds: A method of treating coronavirus infection. The method includes administering to a subject suffering from or being at risk of suffering from such infection an effective amount of a compound of formula (I). Each variable in this formula is defined in the specification....

20060160868 - 3-phenylpropionic acid derivatives: The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or...

20060160867 - Methods for modulating ppar biological activity for the treatment of diseases caused by mutations in the cftr gene: This invention features methods for treating diseases associated with mutations in the CFTR gene by administering PPAR agonists, specifically PPARγ, PPARα, and PPARδ agonists, PPAR inducers, and/or antioxidants. Also disclosed are screening methods for identifying therapeutically useful candidate compounds....

20060160869 - Ubiquitin ligase inhibitors: This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors, particularly ubiquitin ligase inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved, such as signal transduction pathways. The invention also comprises the use...

20060160870 - 3-phenylpropionic acid derivatives: The invention relates to new compounds, 3-phenylpropionic acid derivatives of formula (I) wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R1 to R8 each independently represent hydrogen atom or...

20060160871 - Stable non-crystalline formulation comprising losartan: One or more embodiments of the invention provide various novel formulations, and tablet dosage forms, comprising losartan that are non-crystalline, stable, and/or otherwise improvements over known losartan formulations. One or more embodiments of the invention further provide methods for preparing the formulation, methods for preparing the tablet dosage form, and...

20060160872 - Vanilloid receptor ligands and their use in treatments: Substituted benzimidazoles and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory...

20060160873 - Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis: Medicaments comprising compounds of this type are of use for preventing or treating various disorders, such as, respiratory disorders and snoring, acute and chronic disorders, disorders induced by ischemic and/or reperfusion events and by proliferative or fibrotic events, disorders of the central nervous system and lipid metabolism, diabetes, blood coagulation...

20060160874 - Heterobicyclic pyrazole derivatives as kinase inhibitors: Bicyclo-pyrazoles of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer....

20060160876 - Indole derivatives: Provided herein are indole derivatives, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds....

20060160875 - Matrix metalloproteinase inhibitors: o

20060160877 - 2-heteroaryl carboxamides: The invention relates to novel 2-heteroaryl carboxamides and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory....

20060160878 - N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of a CNS disorder relating to or affected by the 5-HT6 receptor....

20060160880 - 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri: The present invention relates to aniline derivatives of the general formula I and their use....

20060160881 - Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity,...

20060160879 - Indoles useful in the treatment of inflammation: There is provided a compound of formula (I), wherein X, Y, Z, R1, R2, R3, R4, and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of microsomal prostaglandin E synthase-1 is desired...

20060160882 - Indoline derivatives: e

20060160884 - Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase:

20060160883 - Regulation of immune system action in mammals through use of a multi-tiered model of immune system function: This invention is a model of the mammalian immune system, having at least two tiers, and its use in the prevention, screening, testing, treatment and research of a variety of diseases and conditions, all of which produce the enzyme, indoleamine 2,3-dioxygenase (IDO) or inspire the body to produce IDO in...

20060160885 - Chemical compounds: i

20060160886 - Chemical compounds:

20060160887 - Medicinal composition: The present invention provides a pharmaceutical composition which is useful in the treatment for overactive bladder and the like, and comprises 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-d ihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide or a pharmaceutically acceptable salt thereof, and an anticholinergic agent....

20060160888 - Room-temperature stable dronabinol formulations: A room temperature stable cannabinoid formulation is disclosed. In preferred embodiments, the cannabinoid formulation is dronabinol in an oil-based carrier contained within a hard gelatin capsule....

20060160889 - Chroman derivatives as estrogenic compounds: wherein R1 is (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl, and independently R1 has a cis-orientation in relation to the exocyclic phenyl group at the 2-position of the skeleton; R4 is H, Hal, CF3, OH or (1C-2C)alkyloxy; R2, R3, and R5are independently H, Hal, CF3, (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl and prodrugs thereof for...

20060160890 - Triterpenoid derivatives: The present invention relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in therapy. Prefereably, the compound may be used for treating a patient suffering from leukaemia, cancer or other proliferative disorder. A further embodiment relates to the use of a compound of...

20060160891 - Process for producing powdered compositions containing highly unsaturated fatty acid esters of ascorbic acid and powdered compositions containing the esters: The invention provides a process for powdering highly unsaturated fatty acid esters of ascorbic acid which are pasty and problematic in physical properties by a simple and easy means; highly unsaturated fatty acid esters of ascorbic acid which are improved in stability by powdering; and compositions containing the powdered highly...

20060160892 - Methods for treating hyperactive gastric motility: This invention provides methods and pharmaceutical compositions for treating, inhibiting or preventing hyperactive gastric motility in a mammal utilizing agonists of KCNQ potassium channels, including KCNQ2, KCNQ3, KCNQ4 and KCNQ5 potassium channels, alone or in combination. The hyperactive gastric motility may be associated with maladies including, colitis, irritable bowel syndrome...

20060160893 - Method for enhancing the quality of berry fruit: i

20060160894 - Benzamides as ppar modulators: Compounds of general structure (I), wherein the central benzene ring may be substituted in the meta- or para-position; -A is an optionally substituted hydroxyl, alkoxyl, hydroxylamine, alkoxylamine or amine radical; -W is an N- and C-linked biradical selected from several possibilities; and -Z is a carbon radical selected from several...

20060160895 - Anti-cancer agents: m

20060160896 - Therapeutic treatment: The invention describes the use of betaine for treating and preventing arterites. The invention also describes an orally administered composition for treating arterites and, in particular, intermittent claudication, said composition containing, as an active ingredient, an active therapeutic quantity of betaine glycine by single dose. The invention particularly describes a...

20060160897 - Topical use of valproic acid for the prevention or treatment of skin disorders: The present invention relates to a topically applicable formulation containing Valproic Acid or a derivative thereof which can be used alone or in combination with topically applicable formulations of retinoids or of nuclear receptor ligands, or of chemotherapeutic agents (e.g. 5-Fluorouracil). The formulation is useful for the topical treatment of...

20060160898 - Method of using catalpic acid to treat and prevent type 2 diabetes and associated disorders: A method of treating and preventing type 2 diabetes and obesity an animal, including mammals and humans, in which a therapeutically effective amount of catalpic acid to the animal is administered orally or parentally....

20060160899 - Intrathecal gabapentin for treatment of epilepsy: Methods for treating epilepsy by administering gabapentin to cerebrospinal fluid and brain tissue of a patient are discussed. Compositions, particularly injectable compositions, containing gabapentin are also discussed. In addition, systems including an implantable device having a pump coupled to a reservoir for housing a composition, a catheter having a proximal...

20060160900 - Intrathecal gabapentin for treatment of pain: Methods for treating pain by administering gabapentin to cerebrospinal fluid of a patient are discussed. Compositions, particularly injectable compositions, containing gabapentin are also discussed. In addition, systems including an implantable pump having a reservoir for housing a composition, a catheter having a proximal portion coupled to the pump and having...

20060160901 - Method for selective targeting of apoptotic cells and small molecule ligands used thereof: The invention provides novel methods for selective targeting of chemical compounds to cells undergoing a death process, in particular apoptosis, and to platelets undergoing activation during blood coagulation. The invention further provides compounds to be used in said methods for medical practice, for diagnostic and therapeutic purposes....

20060160902 - Histone deacetylase inhibitors: Hormone refractory metastatic disease can be treated with an oxyamide-containing compound through the inhibition of HDAC1 or HDAC2....

20060160903 - Process for preparing benzhydrylthioacetamide: The present invention is directed to an improved process for preparing modafinil wherein benzhydrylthioacetamide is prepared in high yield and purity by the reaction of a haloacetamide with the reaction product of thiourea and benzhydrol in aqueous solution. The reaction employing the haloacetamide is conducted in a solvent comprising water...

20060160904 - Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them: The invention provides compounds of formula (I) in which m, n, R?1, R?2, R?3, R?4 and R?5 have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy....

20060160905 - Compositions and methods for inhibiting pain: R and R1 are the same or different and may be H or linear or branched chain alkyl having 1 to 8 carbon atoms, m is an integer from 0 to 10, inclusive and wherein the amine exhibits a mean reduction in abdominal writhings exhibited by mice in the standard...

20060160906 - Polyamine analogs as therapeutic agents for ocular diseases: This disclosure relates to methods of treating ocular diseases using polyamine analogs, particularly conformationally restricted polyamine analogs. The ocular diseases to be treated include a variety of ophthalmic disorders characterized by angiogenesis and/or neovascularization, including macular degeneration. Both wet macular degeneration and dry macular degeneration can be treated using the...

20060154852 - Beta sheet tapes ribbons in tissue engineering: There is described a material comprising ribbons, fibrils or fibres characterised in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a beta-sheet-tape-like substructure....

20060154853 - Method of treating an autoimmune disease: The present invention relates generally to a method for treating or ameliorating the symptoms of or reducing or otherwise minimizing the risk of development of an autoimmune disease such as but not limited to autoimmune diabetes. More particularly, the present invention relates to the use of genetically modified hemopoietic stem...

20060154854 - Molecules for targeting and releasing therapeutic compounds, and the use thereof: The invention relates to chimera molecules for targeting and releasing therapeutic compounds in mammals, especially humans. The inventive molecules comprise essentially three functional segments or domains: a targeting segment that can preferentially bind to the surface of the targeted cells, a therapeutic segment comprising the biologically active compound, and a...

20060154855 - Methods and compositions for beta conglycinin fraction of soy protein: The present invention provides compositions and methods useful for preventing and/or treating a cardiovascular disorder such as atherosclerosis, coronary heart disease, myocardial infarction, and stroke in a subject, comprising administering to the subject an effective amount of β-conglycinin, with or without soy isoflavones....

20060154857 - Compositions for down-regulation of ccr5 expression and methods of use thereof: The present invention relates to the downregulation of surface receptor CCR5 expression through manipulation of the cell cycle in activated lymphocytes by administering a composition that arrests the G1 phase of the cell cycle, thereby reducing receptor sites for entry of HIV into T cells, and thus, the effects of...

20060154856 - Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities: The invention relates to compositions and methods for treating Obstructive Sleep Apnea (OSA). Specifically, the invention relates to the use of NADPH Oxigenase inhibitors in compositions and methods for treating OSA in a subject....

20060154858 - Canine rankl and methods for preparing and using the same: The present invention provides isolated nucleic acid molecules that encode a substantial part of canine RANKL polypeptide, including the extracellular domains of that polypeptide, the polypeptide and fragments thereof. Vectors and host cells encoding and expressing canine RANKL polypeptide are provided, as well as antibodies that bind to RANKL and...

20060154866 - Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the...

20060154867 - Compounds for targeting hepatocytes: We describe compounds that bind to and are internalized by hepatocytes. Association of these compounds to other molecules or complexes can be used to target the molecules or complexes to hepatocytes in vivo or in vitro....

20060154865 - Conjugates of insulin-like growth factor-1 and poly(ethylene glycol): A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or...

20060154868 - Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis: A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one...

20060154859 - Leptin antagonists: The invention relates to synthetic leptin antagonists in which at least two amino acid residues of the sequence LDFI/S of the hydrophobic binding site at positions 39-42 of a leptin polypeptide sequence are substituted with different amino acid residues such that the site becomes less hydrophobic, and fragments of said...

20060154869 - Liver regeneration promoting agent: Although it is known that adiponectin, which is adipose-specific protein, has effects of suppressing the proliferation and migration of vascular smooth muscle, an effect against arteriosclerosis, an effect of inhibiting the activation of monocytes and macrophages and an anti-inflammatory effect, its action on hepatic stellate cells has never been known...

20060154860 - Manipulating stem-progenitor cell trafficking to injured tissue and/or tumors by altering hif-1 and/or sdf-1 activity: The present invention relates to a method for modulating recruitment of stem cells or progenitor cells to a selected tissue site. Methods for treating damaged tissue and for treating cancerous tumor tissue are also disclosed. These methods involve regulating HIF-1 and/or SDF-1 activity in the tissue....

20060154870 - Method for prevention or treatment of diseases or disorders related to excessive formation of vascular tissue or blood vessels: This invention concerns a method for treating or preventing a disease or disorder related to excessive formation of vascular tissue or blood vessels in a patient, said method comprising administering to said patient an agent affecting the NPY Y2 receptor....

20060154861 - Method for screening substances capable of inhibiting the hyperplasia of pancreatic cells and/or the hypersecretion of insulin by pancreatic cells: There are provided PACAP which is a substance capable of inhibiting the hyperplasia of pancreatic cells and/or the hypersecretion of insulin by pancreatic cells, a method for inhibiting the hyperplasia of pancreatic cells and/or the hypersecretion of insulin by pancreatic cells in a human by PACAP administration, a pharmaceutical composition...

20060154863 - Methods and compositions for treating conditions: The invention relates to compositions comprising of SEQ NO: 1-244, 248-249, and any homologs, analogs, and fragments thereof. Such compositions can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions can be formulated with an acceptable pharmaceutical excipient...

20060154862 - Processes for preparing a polypeptide: The present invention relates to processes for preparing a polypeptide or pharmaceutically acceptable salt thereof comprising L-tyrosine, L-alanine, L-glutamate and L-lysine. The polypeptide or pharmaceutically acceptable salt thereof is preferably glatiramer acetate....

20060154864 - Transcript factor and an akt substrate related to transcriptional action of insulin and applications of same: A transcription factor capable of activating multiple insulin-responsive genes. In one embodiment, the transcription factor includes an NH2-domain containing thirteen epidermal growth factor (EGF)-like repeats proximate to the N-terminus, a solitary calcium-binding EGF-like domain proximate to the C-terminus, and three consecutive fibronectin type III (fn3) domains between the NH2-domain and...

20060154871 - Peptides: The amino acid sequence of several peptides present in Colostrinin is disclosed. These peptides are useful, inter alia, in the treatment of disorders of the immune system and the central nervous system....

20060154872 - Hemiasterlin derivatives and uses thereof: e

20060154873 - Aseptic combination preparation: There is provided an aseptic combination preparation to be mixed at the time of use, characterized in that the same medicinal ingredients are divided and preserved in two or more chambers. The aseptic combination preparations according to the present invention are a mixing type at the time of their use...

20060154875 - Thienoisoquinoline-phenylsulfonamides and their use as er-nfkappab inhibitors: e

20060154874 - Treatment of symptoms associated with bacterial vaginosis: The invention relates to the use of saccharide, such as lactose for the preparation of a medicament for the treatment and/or prophylaxis of one or more symptoms caused by bacterial vaginosis, wherein the medicament comprises at least 20 percent by weight of saccharide, and wherein the medicament is substantially free...

20060154877 - Hemiterpene glycosides with anti-platelet aggregation activities from ilex pubescens: Two hitherto unreported novel hemiterpene glycosides were isolated in substantially pure form from the root of Ilex pubescens. The chemical structures and some properties of these hemiterpenes have been elucidated. These hemiterpene glycosides possess anti-platelet aggregation activity more potent than those of salvianolic acid B and aspirin and may be...

20060154876 - Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis: A serum cholesterol lowing agent or a preventive or therapeutile agent for atherosclerosis, which each comprises a combination of a compound represented by the following general formula (I) or pharmaceutical acceptable salts thereof with a cholesterol biosynthesis inhibitor and/or a fibrate type cholesterol lowing agent. (I) (b) (a) [In the...

20060154881 - 9a,11-2c-bicyclic 9a-azalide derivatives: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the...

20060154879 - Avermectins substituted in the 4\" and 4'-positions having pesticidal properties: What is described are a compound of the formula (I) Wherein A-B is —CH═CH— or —CH2—CH2—; n is 0 or 1; R1, is C1-C12alkyl, C3-C8cycloalkyl or C2-C12alkenyl; R2 and R3 for instance are either, (i) independently from each other for instance -Q, —C(═Y)-Q, or —C(═Y)—O-Q; or (ii) together form with...

20060154880 - Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases: Methods of treating, preventing and/or managing various protozoan parasitic disease and disorders are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone, or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with conventional anti-parasitic treatments...

20060154878 - New 3-decladinosyl derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin a 9a, 11-cyclic carbamates: The present invention relates to the new 3-decladinosyl derivatives of 9-de-oxo-9a-aza9a-homoerythromycin A 9a,11-cyclic carbamate of the general formula (I), their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates, wherein R1 individually stands for hydrogen, hydroxyl or a group of the formula (II), wherein X individually stands...

20060154890 - Immunostimulatory nucleic acids for the treatment of asthma and allergy: The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an asthma/allergy medicament for the treatment or prevention of asthma and allergy in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates...

20060154888 - Lna oligonucleotides and the treatment of cancer: The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5′-(MeCx)(Tx)MeCxAsAstscscsastsgsgsMeCxAx(Gx)(c)-3′, and preferably of the general formula 5′-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3′, wherein capital letters designate an LNA nucleotide analogue selected from β-D-oxy-LNA, β-D-thio-LNA, β-D-amino-LNA and α-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as...

20060154882 - Methods for blocking adipocyte differentiation and triglyceride accumulation with g-alpha-i3 inhibitors: Methods for blocking adipocyte differentiation and triglyceride accumulation with inhibitors of G-alpha-i3 are provided. G-alpha-i3 inhibitors of the present invention include small molecules, antibodies, peptides (including dominant negative peptides) and antisense compounds, including ribozymes, inhibitory RNA molecules including siRNA molecules and antisense oligonucleotides....

20060154885 - Modulation of slc26a2 expression: Compounds, compositions and methods are provided for modulating the expression of SLC26A2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SLC26A2. Methods of using these compounds for modulation of SLC26A2 expression and for diagnosis and treatment of disease associated with expression of SLC26A2 are provided....

20060154883 - Nonsense-mediated mrna decay: Disclosed are compositions and methods relating to nonsense mediated decay (NMD) particularly in the “pioneer” round of translation. The present invention provides methods of treating disorders relating to NMD and methods of screening substances for use in the study of or treatment of conditions relating to NMD....

20060154889 - Polyfluorinated nucleoside analogs and methods of use thereof: Nucleoside analogs comprising polyfluorinated benzene, pyrrole, pyridine, indole, isoindole, or benzoimidazole rings are shown to provide for selective base pairing with self, or other polyfluorinated analogs, in preference to native nucleic acid bases. The analogs of the invention stabilize the stacking of helices, and increase hydrophobicity when introduced into an...

20060154886 - Regulatory elements in the 5' region of the vr1 gene: A nucleic acid comprising a sequence section which modulates the expression of the VR1 receptor, a vector containing this nucleic acid and a host cell which is transformed with this vector are disclosed, along with related pharmaceutical formulations. Methods for modulating the expression of the VR1 receptor and the use...

20060154884 - Use of a vegf receptor gener or gene product: The invention relates to the use of a VEGF receptor gene or receptor for the prevention or treatment of restenoses, ischaemia, arteriosclerosis and other cases of exuberant proliferation. The invention especially relates to the use thereof in therapy following balloon catheter treatment of the coronary vessels. The invention also relates...

20060154887 - Use of apoptosis-specific eif-5a sirnas and antisense polynucleotides to inhibit/suppress an inflammatory response: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or...

20060154892 - Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis: A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus. Hydroxyurea is one such suitable compound. Also...

20060154891 - Ready-to-use gemcitabine solutions and gemcitabin concentrates: Pharmaceutical compositions in the form of ready-to-use preparations of gemcitabine in aqueous solutions in a glass containers having specified dimensional relationships demonstrate long shelf life over a wide range of solution pH values. The ratio of the surface area of the container wetted by the solution to the volume of...

20060154894 - Biologically active surfaces and methods of their use: The invention relates to the immobilization of polysaccharides on a substrate. In particular, the invention relates to biologically active surfaces formed by the immobilization of glycosaminoglycans on a substrate. The invention also provides biologically active surfaces that contain one or more different glycosaminoglycans and, optionally, one or more other agents....

20060154893 - Exopolysaccharides delivery system for active molecules: The present invention relates to a delivery system for delivery of an active molecule to a patient, the delivery system comprising a population of exopolysaccharide micelles, each micelle defining a core for containing the active molecule....

20060154895 - Method of treating acquired immunedeficiency syndrome: HIV infections are treated with sequential treatment regimens comprising a first regimen which is a combination of highly active antiretroviral therapy drugs selected from the group consisting of nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors to reduce the HIV levels; and a second treatment regimen which...

20060154896 - Phosphorylated dextrans: Dextrans, which have no immunoreactivity, were revealed to exert immunopotentiating activities on their chemical phosphorylation. Since phosphorylated dextrans not only function as B cell mitogens, but also activate dendritic cells and induce IL-10 and IFN-γ, they can be expected to have effects in preventing infectious diseases and colitis, and in...

20060154897 - Ophthalmic compositions for treating ocular hypertension: This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective...

20060154898 - Diphosphonate solutions: A pharmaceutical product containing pamidronate and other diphosphonate solutions in an appropriate container, a pH of between 5 and 8 and without organic acid buffer or polyethylen glycol. The container may be treated glass or made of other appropriate material. Coated elastomeric stoppers are also included. A method of producing...

20060154899 - Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of...

20060154900 - Diphosphonate solutions: A pharmaceutical product containing pamidronate and other diphosphonate solutions in an appropriate container, a pH of between 5 and 8 and without organic acid buffer or polyethylen glycol. The container may be treated glass or made of other appropriate material. Coated elastomeric stoppers are also included. A method of producing...

20060154901 - Methods for treating ocular rosacea: A method for treating a patient having meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion, is disclosed. Preferably, the method concerns treatment of a patient with topical tetracycline, a derivative or analogue of tetracycline, or a chemically modified tetracycline (CMT). Oral administration of...

20060154902 - Shortening of hospital stay and improving survival in patients with chronic kidney disease: Formulations containing a Vitamin D compound or analog, such as paricalcitol (Zemplar™) are useful for shortening hospital stays in chronic kidney disease patients with or without hyperparathyroidism. Also disclosed are methods of shortening hospital stays for chronic kidney disease patients with or without hyperparathyroidism, and methods for determining reduction length...

20060154903 - Betulinol derivatives as anti-cancer agents: r

20060154904 - Betulinol derivatives as anti-hiv agents: The present invention relates to methods of treating HIV-1 infection in a subject. These methods involve administering to the subject with HIV-1 infection a therapeutically effective amount of a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject...

20060154906 - Methods and related compositions for the non-surgical removal of fat: Compositions and methods useful in the non-surgical removal of localized fat deposits in patients in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion agents and pharmaceutically acceptable excipients but do not contain phosphotidylcholine. The pharmacologically active detergent compositions...

20060154905 - Nitrate esters of corticoid compounds and pharmaceutical applications thereof: m

20060154907 - Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy: The present invention combines the administration of estrogens with the administration of non-aromatizing androgens to treat hormonal deficiencies in women undergoing estrogen replacement therapy....

20060154908 - Co-administration of dehydroepiandrosterone (dhea) congeners and other active agents for treating depression: The present invention is drawn to compositions and methods for treating depression in a subject comprising co-administering therapeutically effective amounts of a DHEA congener and a second antidepressant agent to the subject, wherein the step of co-administrating is more effective in producing an anti-depressive effect compared to the administration of...

20060154909 - 1,4,6-androstatriene-3,17-dione (\"atd\") for therapeutic uses: A composition having modified or derivative of 1,4,6-androstatriene-3,17-dione (“ATD”) will improve the health of mammalian subjects. The improvement of health is achieved with the administration of an effective amount of the at least one modified or derivative of 1,4,6-androstatriene-3,17-dione. Particularly, health is improved for a subject suffering with a gynecomastia,...

20060154910 - Use of steroids to treat ocular disorders: Methods and compositions for treating retinal edema and NPDR are disclosed....

20060154911 - Apoptosis-inducing antineoplastic silver (i) coordination complexes: The present invention describes chemotherapeutic compositions, a method for making the same, and methods for inducing apoptosis in tumor cells and/or inhibiting tumors. The compositions are metal coordination complexes of a cytotoxic metal, such as silver(I) and a chiral α-organic acid, such as tartaric acid, in a pharmaceutical carrier....

20060154912 - Isophtalic acid derivatives: The present invention relates to isophthalic acid derivatives, to a process for their preparation and to their use for producing medicaments for the treatment and/or prophylaxis of diseases in humans and animals, in particular of cardiovascular disorders....

20060154913 - Respiratory syncytial virus replication inhibitors: This invention concerns the use of compounds of formula (I) wherein -a1=a2-a3=a4- is a radical of formula —CH═CH—CH═CH—, —N═CH—CH═CH—, —CH═N—CH═CH—, —CH═CH—N═CH—, —CH═CH—CH═N—wherein each hydrogen atom may optionally be substituted; Q is a radical of formulas (b-1), (b-2), (b-3), (b-4), (b-5), (b-6), (b-7), (b-8). G is a direct bond or C1-10alkanediyl;...

20060154914 - Dibenzoxazepinone derivatives and uses thereof: i

20060154915 - Substituted biaryl compounds as factor xia inhibitors: or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, and ring B are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin,...

20060154916 - Condensed azepines as vasopressin agonists: This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, OPh, O-acyl, N3, NH2, NHBn or NH-acyl and the...

20060154917 - Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators: (Heterocycloalkyl)methyl azole derivatives of Formula (I) are provided: Formula I wherein A is oxygen, sulfur, or NR; J and K and each L are independently oxygen, sulfur, NH, or CH2; and the remaining variables are defined herein. Such compounds are modulators of C5a receptors, and preferably bind to C5a receptors...

20060154920 - 1,2,3,4,7,8-hexahydro-6h-[1,4]diazepino[6,7,1-ij] quinoline derivatives as antipsychotic and antiobesity agents: e

20060154919 - Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof: An antipsychotic and GlyT1 inhibitor combination is disclosed. The antipsychotic and GlyT1 inhibitor combination may be employed in the prevention and treatment of symptoms of schizophrenia. Pharmaceutical compositions and treatments comprising an antipsychotic and a GlyT1 inhibitor for treating symptoms of schizophrenia are thus also disclosed....

20060154918 - Injectable nanoparticulate olanzapine formulations: Described are injectable formulations of nanoparticulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise nanoparticulate olanzapine....

20060154921 - Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients: The invention relates to a method of treatment or prevention of hot flushes in men who underwent castration, e.g. due to androgen ablation treatment in prostate cancer therapy, comprising administration of an effective amount of a selected CGRP antagonist to the patient, and to the use of said active compounds...

20060154922 - Muscarinic agonists: The present invention relates to compounds of Formula (I): which are agonists of the M-1 muscarinic receptor....

20060154923 - N-phenyl-3-cyclopropylpyrazole-4-carbonitriles as ectoparasiticidal agents: e

20060154924 - Fungicidal mixtures based on morpholine or piperidine derivatives and oxime ether derivatives:

20060154925 - Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof: wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by...

20060154927 - Fungicidal mixtures for combating rice pathogens: e

20060154926 - Methods of treating alzheimer's disease using aryl alkanoic acid amides: Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of compounds of formula (1) wherein the variables R1-R8 and X are defined herein....

20060154928 - Novel 2,4-diamino-1,3,5-triazine derivative: s

20060154930 - Substituted amino heterocycles as vr-1 antagonists for treating pain: The present invention provides compounds of formula I: in which: one of T1 and T4 is N and the other is C; T2 and T3 are independently N or C(CH2)nR2; X, Y and Z are independently N or C(CH2)nR3; R1 is Ar1 or R1 is C1-6alkyl optionally substituted with one...

20060154929 - Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds: 6H-pyrrolo[3,4-d]pyridazine compounds and methods of their use of as ligands of voltage gated calcium channels (VGCC), useful in the treatment of neuropathic pain, and psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive...

20060154931 - Heteroaromatic quinoline compounds: The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in...

20060154932 - Pharmaceutical compositions and method of treating parkinson's disease: This invention is directed to the use of certain pharmaceutical compositions for treating and methods of treating Parkinson s disease. In particular, this invention is directed to pharmaceutical compositions for treating and methods of treating Parkinson s disease comprising the use of selective cyclooxygenase-2 inhibitors, such as rofecoxib, etoricoxib, celecoxib...

20060154933 - Inhibitors of cdc25 phosphatases: i

20060154934 - Combinations comprising antimuscarinic agents and pde4 inhibitors: Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma...

20060154935 - Quinazolines useful as modulators of ion channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders....

20060154936 - Use of n-'5-'4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension: e

20060154937 - Novel farnesyl protein transferase inhibitors and their use to treat cancer: wherein R8 represents a cyclic and acyclic moiety to which is bound an imidazolylalkyl group; R9 represents a carbamate, urea, amide or sulfonamide group; and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the...

20060154938 - Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram,...

20060154939 - Medicaments for the treatment or prevention of fibrotic diseases: e

20060154940 - Processes for preparing pyrazolo[3,4-d]pyrimidine ethers: The present invention relates to processes for preparing pyrazolo[3,4-d]pyrimidine ether compounds that are modulators of glucose metabolism and therefore useful in the treatment of metabolic disorders such as diabetes and obesity....

20060154942 - Quinazolinone derivatives useful as anti-hyperalgesic agents: The present invention relates to quinazolinones of formula (I) wherein R1 is hal; a); b); or c); X is N or CR8; R2 is hal; nitro; C1-C6alkylcarbonyl; C1-C6alkyl or C3-C6cycloalkyl; R3 is C1-C6alkyl; C1-C6alkoxy or amino; and wherein the further radicals have the meanings as defined in the specification, which...

20060154941 - Novel amorphous form of erlotinib hydrochloride and its solid amorphous dispersion: The present invention relates to novel amorphous form of [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl) (erlotinib hydrochloride), to solid amorphous dispersion of erlotinib hydrochloride and a carrier such as PVP or solid PEG, to processes for their preparations, to pharmaceutical compositions containing them and to method of treatment using the same. The amorphous form or...

20060154943 - Benzofuran derivatives and their use in the treatment of microbial infections: The invention relates to new benzofuran derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as anti-infectives....

20060154944 - Novel tricyclic heterocycle compound: (wherein A is a cyclic group which may have a substituent(s); X is a single bond or a spacer; Y is a single bond or a spacer; Z is a single bond or a spacer; B is a hydrocarbon group which may have a substituent(s) or a cyclic group which...

20060154945 - Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor: and pharmaceutically-acceptable salts thereof, wherein Q, Ar1, A and Ar2 are as defined in the specification, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them, uses...

20060154946 - Method for treating eating disorders by selective extinction with transdermal naloxone: A method for treating eating disorders by repeatedly administering naloxone in a dosage sufficient to block the effects of opiate agonists to a subject suffering from an eating disorder caused by one or more related problem responses; while the amount of naloxone in the subject's body is sufficient to block...

20060154947 - Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in manufacture of medicaments: The invention relates to alkaloid reaction products obtainable in a process wherein alkaloids are reacted with an alkylating agent, preferably thiotepa, whereafter unreacted alkylating agent and other water-soluble compounds are removed from the reaction mixture by washing with water or a suitable aqueous solvent, whereafter the reaction mixture is subjected...

20060154949 - Arylindenopyridines and related therapeutic and prophylactic methods: e

20060154948 - Treating allergic and inflammatory conditions: The use of desloratadine for the preparation of a medicament for treating and/or preventing an allergic and inflammatory condition of the skin or upper and lower airway passages in a pediatric patient and a pediatric pharmaceutical composition effective for such treating and/or preventing which comprises an effective amount of desloratadine...

20060154953 - Amorphous tacrolimus and preparation thereof: The present invention provides amorphous tacrolimus in a free drug particulate form. Also provided are methods for preparing amorphous tacrolimus, and a tablet containing amorphous tacrolimus....

20060154950 - Novel use of rapamycin and structural analogues thereof: The use of rapamycin and its structural analogues for the preparation of a medicament for the therapeutic treatment of beta-thalassaemia is described....

20060154952 - Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation-and ummunologically-mediated diseases: The present invention relates to pharmaceutical compositions comprising in combination rapamycin or a rapamycin derivative and a compound of formula I, e.g. useful for the treatment of inflammatory and immunologically-mediated diseases, including autoimmune diseases....

20060154951 - Quaternary antimuscarinic compounds for the treatment of bladder diseases: The present invention relates to a method for treating bladder disease, including urinary incontinence, which involves intravesical administration of quaternary antimuscarinic compounds having longer duration of effect and fewer side effects than standard treatments....

20060154954 - Combinations and use of selected pharmaceutically active compounds: The present invention relates to new combinations and new uses of certain selected tricyclic imidazo [1,2-a]pyridine compounds in the prevention or treatment of medicament caused gastrointestinal diseases....

20060154955 - Bicyclic heterocycles as cannabinoid receptor modulators: e

20060154956 - Bicyclic heterocycles as cannabinoid receptor modulators:

20060154958 - Bicyclic heterocycles as cannabinoid receptor modulators:

20060154957 - Crystalline clopidogrel hydrobromide and processes for preparation thereof: Provided are crystalline forms of clopidogrel hydrobromide and processes for their preparation....

20060154959 - Combination therapies of cicletanine and carvedilol: Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and carvedilol for treating and/or preventing...

20060154960 - Phosphodiesterase 4 inhibitors: Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs....

20060154961 - Thiadiazole compounds and methods of use: The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders....

20060154962 - Heterocyclic modulators of the glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof: e

20060154963 - Pten inhibitor or maxi-k channels opener: wherein R is cycloalkyl, A is lower alkylene, and the bond between 3- and 4-positions of the carbostyril nucleus is single bond or double bond, or a salt thereof, which is useful as a medicament for promotion of the survival of normal cells, brain cells, heart cells, and skin, and...

20060154964 - Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof: Compounds of general formula: (formula I) wherein R1, R2, R3, R4, and R5 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain....

20060154965 - Tetralin and indane derivatives and uses thereof: m

20060154966 - Novel raloxifene acid additon salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these: Raloxifene acid addition salts or solvates thereof, having improved dissolution properties in media comprising hydrochloric acid are described, compared with similar preparations based on raloxifene or raloxifene hydrochloride. The disclosed acid addition salts or solvates thereof show an improved bioavailability in media comprising hydrochloric acid, such as the gastric juice....

20060154967 - Chemical compounds: A compound of formula (I):, where A is an ortho-substituted ring selected from a number of specified rings; R1 is halogen, cyano, nitro, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy or C1-4 haloalkoxy or optionally substituted C2-4 alkenyl, optionally substituted C2-4 alkynyl or optionally substituted SO2(C1-4 alkyl) (where the optionally substituted...

20060154968 - Treating neurological disorders using selective antagonists of persistent sodium current: The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current....

20060154969 - Adenosine receptor selective modulators: The invention relates to the compounds of formula (I), to a method for producing the same and to the use thereof as medicaments....

20060154970 - Alanines compounds, method of preparing them and their use: In the formula (I), the configuration of α-Carbon atom of alanine is R or S; R1 is hydrogen, unsubstituted or substituted C1-6alkyl, unsubstituted or substituted aryl or aromatic heterocyclic group; R2 is hydrogen or unsubstituted or substituted C1-6 alkyl. The present invention also provides two methods of preparing these compounds...

20060154971 - Combination therapies of cicletanine and lacidipine: Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and lacidipine (a preferred calcium antagonist)...

20060154972 - Amino acids with affinity for the alpha-2-delta-protein: This invention relates to certain β-amino acids that bind to the alpha-2-delta (α2δ) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders....

20060154973 - Substituted heteroaryl amide modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof: including all stereoisomers thereof, tautomers thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein X is selected from N, O, and S; Y is N or CR6; Z is a ring; and where R, Ra, Rb, Rc, Rd, R1, R2, R3, R4, and R5 are as defined...

20060154975 - Modulators of the glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof: c

20060154974 - N-thiazol-2-yl-benzamide derivatives:

20060154976 - Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors: A method of treatment of indications which can be positively influenced by inhibition of AT1 mediated effects with maintenance of AT2 receptor mediated effects of angiotensin II and by ACE inhibition, thus also increasing bradykinin mediated effects, e.g., to reduce the incidence of stroke, acute myocardial infarction or cardiovascular death,...

20060154977 - Therapeutic molecules and methods-1: Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) as defined herein, is provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of...

20060154978 - Biocides and apparatus: There are provided methods for controlling microbial or bioflim growth, comprising mixing a hypochlorite oxidant and at least one nitrogen-containing compound or salt thereof selected from a particular group of nitrogen-containing compounds and salts to form a biocide, and applying the biocide. Apparatus for practicing the methods are also provided....

20060154979 - Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity: The use is described of derivatives of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with formula (i): in which the substituents have the meanings described in the text, for the preparation of a medicine for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, its complications, the various forms of insulin resistance,...

20060154980 - Improved cox-2 inhibitory compositions and therapeutic regimen: This invention provides improved COX-2 inhibitory compositions comprising a combination of a selective inhibitor of COX-2 and a prostacyclin promoter, especially an antioxidant of the type known as food extracts. The invention also provides a regimen treating a disease that is responsive to inhibition of cyclooxygenase-2, comprising administering to a...

20060154981 - Method of reducing intraocular pressure and treating glaucoma: The use of 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular hypertension and glaucoma is disclosed....

20060154982 - Use of cyklolignans and new cyklolignans: Compounds which inhibit the insulin-like growth factor-1 receptor (IGF-1 R) and methods for using them for treating IGF- 1 R dependent diseases, such as cancer....

20060154983 - Use of a composition comprising vitamin k1 oxide or a derivative thereof for the treatment and/or the prevention of mammal dermatological lesions: The present invention is related to the use of a composition having an adequate pharmaceutical or cosmetic carrier or diluent and a sufficient amount of vitamin K1 oxide or its derivative for the treatment and/or the prevention of mammal dermatological lesions. The present invention is also related to a cosmetic...

20060154984 - Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof: The invention relates to the use of acyl glycerols and the nitrogen- and sulfur-containing analogues thereof in the therapeutic field, particularly in human health. The inventive compounds have advantageous pharmacological properties and are particularly of use for the prevention or treatment of neurodegenerative diseases....

20060154985 - Antitumoral d-homoestra-1,3,5 (10)-trien-3-yl 2-substituted sulfamates: This invention relates to 2-substituted D-homo-estra-1,3,5(10)-trien-3-yl sulfamates of general formula I (I), in which R3 means a C1-C5-alkyl or C1-C5-alkyloxy group as well as their use for the production of a pharmaceutical agent for treating tumor diseases, which can be influenced positively by the inhibition of tubulin polymerization. The compounds...

20060154986 - A triacylglyceride to deliver health promoting fatty acids to the upper gastrointestinal tract and skin: wherein, each R, independently, is a fatty acid residue, either saturated or unsaturated, having between 2 and 40 carbons; each R′, independently, is a long chain omega-3-unsaturated fatty acid residue having between 16 and 40 carbons, preferably 18 to 22 carbons; and each R″, independently, is a short chain acid...

20060154987 - Method for the preparation of crystalline dexloxiglumide and products obtained: The present invention describes a novel method for the purification of dexloxiglumide by crystallization from isopropyl ether which permits the production, in a reproducible manner, of a product with morphological and particle-size characteristics such as to favour its use in the preparation of oral pharmaceutical forms on an industrial scale....

20060154988 - Antibacterial agents: e

20060154989 - Trimeric, macrocyclically substituted halo-benzene derivatives:

20060154990 - Use of mek inhibitors in treating abnormal cell growth: This invention relates to use of the compound N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide for treating abnormal cell growth in mammals. In particular, the invention provides dosage regimes for administration of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to mammals suffering from cancer....

20060154991 - Inhibitors of candida albicans: The invention provides methods for identifying modulators of yeast phenotypic transitions and methods for treating fungal infections with modulators of phenotypic transitions of yeast cells. These methods include methods for identifying inhibitors of the budded-to-hyphal transition of Candida albicans and methods for treating fungal infections with inhibitors of the budded-to-hyphal...

20060154992 - Enantiomers of o-desmethyl venlafaxine: This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine, R(−)-4-[2-(Dimethylamino-1-(1-hydroxycyclo-hexyl)ethyl)phenol or R(−)1 -[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, or one or more pharmaceutically acceptable salts or salt hydrates thereof, as well as pharmaceutical compositions utilizing these enantiomers and methods of using the enantiomers to treat, inhibit or control...

20060154993 - Method for treating and preventing male infertility: The present invention relates to a novel method of treating male infertility such as, for example, idiopathic asthenospermia. In one aspect the present invention relates to the treatment or prevention of male infertility through the administration of a composition containing ubiquinone, ubiquinol or both, and optionally, a member chosen from...

20060148675 - Methods of reducing angiogenesis: The present invention provides methods of reducing angiogenesis in an individual. The methods generally involve administering to the individual an effective amount of a nicotinic acetyl choline receptor antagonist. The methods are useful to treat conditions associated with or resulting from angiogenesis, particularly pathological angiogenesis. The invention further provides methods...

20060148674 - Therapeutic composition: An anti-mitotic composition with a therapeutic index greater than 1.1, a clonogenic survival rate of less than 0.1 percent, and a binding affinity index for a class II, a class III, or a class V beta tubulin isotype of at least about 1.1....

20060148676 - Polyamino acid-based particle insulin formulation: This invention relates to dual-release formulations of insulin comprising polyamino acid particles and insulin, and a method of preparing such formulations...

20060148677 - Chondrogenesis stimulator: There are provided a chondrogenesis stimulator containing MTf, a chondrogenic differentiation suppressing agent containing an MTf antagonist, a screening method for obtaining an MTf activating agent, an MTf activating agent obtained by the screening method, a chondrogenesis stimulator containing an MTf activating agent as obtained by the screening method, and...

20060148678 - Novel acyl-dipeptide-like compounds, a method for preparing the same and pharmaceutical compositions containing such products: wherein substituents A, B, X, Y, R1, R2, and subscripts n, m, p and q have the same meanings as those given in the claims. The invention is equally directed to pharmaceutical compositions containing as an active ingredient at least one compound of general formula I either in acid or...

20060148680 - Glycoproteins produced in plants and methods of their use: Methods of increasing the yield in plant expression of recombinant proteins comprising: engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein)...

20060148679 - Glycosolated enkephalin agents: It is taught here that enkephalin peptides which are glycosylated with a disaccharide will be transported across the blood brain barrier and deliver analgesic effects superior to morphine when introduced into the bloodstream. Glycosylated peptides with disaccharides attached are superior to analogous peptides with either mono- or tri-saccharides attached....

20060148681 - Method for treating tumor and/or preventing tumor metastasis and relapse: The present invention provides a method for treating tumor and/or preventing tumor metastasis and relapse comprising administrating a subject with a therapeutically effective amount of lectin capable of binding to the tumor and having tumor cytotoxicity and/or lymphocyte activation activity....

20060148682 - Tumor-activated prodrug compounds and treatment: The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (Z) linked to a terminal group (W), characterized in that the linkage between the arm...

20060148683 - Detection and treatment of intravascular lesions: Optical agents that contain a fibrin binding moiety covalently linked to an optical dye are described, as well as methods of treating intravascular lesions in a patient using such optical agents....

20060148684 - Use of a histone deacetylase inhibitor for treating muscular dystrophies: The invention relates to an inhibiter of histone deacetylase for treating or preventing a disease resulting from the deficiency of an adult gene in an individual by the re-expression of the homologous fetal gene. The invention concerns in particular the treatment of dystrophies such as Duchenne's dystrophy or Becker's dystrophy...

20060148685 - Use of substances with oxytocin activity against climacteric disorders: The present invention relates to the use of substances with oxytocin activity against climacteric disorders or similar symptoms due to dysfunction in the ovaries. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against climacteric disorders....

20060148686 - Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy: The invention comprises a method of treating dry eye in a patient in need of such treatment. The treatment comprises administering to a patient in need thereof an ophthalmic pharmaceutical composition comprising a corticosteroid and cyclosporine. In a further embodiment of the invention the corticosteroid is loteprednol etabonate. In yet...

20060148708 - C5a receptor: A human C5a receptor polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for identifying antagonists and agonists to such polypeptide. Antagonists and agonists may be used therapeutically to inhibit or stimulate...

20060148693 - Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases: The invention relates to the combined administration of a pulmonary surfactant and a PDE5 inhibitor for the treatment of a disease in which pulmonary surfactant malfunction and/or phosphodiesterase 5 (PDE5) activity is detrimental....

20060148706 - Composition for wound healing and use thereof: The invention relates to a method for treatment of wound healing, comprising administering to a patient in need of such treatment with an effective amount of a polypeptide comprising amino acid sequence or a conservative variant thereof having EGF-like domain of thrombomodulin. The invention also relates to a composition for...

20060148699 - Counterion exchange process for peptides: The invention encompasses a process for purifying a peptide comprising loading a peptide onto a RP-HPLC column; washing the column with an aqueous solution of a pharmaceutically acceptable counterion salt; and eluting the peptide from the column with a solvent mixture of a organic solvent and an acid of the...

20060148694 - Inhibition of stress-induced ligand-dependent egfr activation: The present invention relates to the inhibition of stress-induced receptor tyrosine kinase activity by inhibiting a ligand of said receptor tyrosine kinase, particularly an extracellular ligand....

20060148700 - Methods and compositions for reducing injury to a transplanted organ: Methods for reducing injury to a transplanted mammalian organ or tissue, including inhibiting the development of graft blood vessel disease, are provided. In one form, a method includes administering compositions that include one or more PKC regulators to an organ or tissue donor and an organ or tissue recipient. Methods...

20060148697 - Methods for treating and preventing brain cancers: Methods are provided for treating brain cancer, preventing or slowing proliferation of cells of prostate origin, preventing brain cancer in a patient at risk of contracting brain cancer, preventing or inhibiting an upregulation of the cell cycle in brain-derived cells in a patient, and decreasing the level of brain cancer-specific...

20060148702 - Methods of increasing cerebral blood flow: Methods of increasing blood flow in a mammalian brain blood vessel characterized by, or otherwise experiencing, decreased blood flow due to an ischemic or other hypoxic event, vasoconstriction or vasospasm following hemorrhagic stroke; due to chronic high blood pressure; and/or due to idiopathic causes are provided. The method for increasing...

20060148709 - Neuroprotective properties of gdf-15, a novel member of the tgf-beta superfamily: The present invention relates to a transforming growth factor-beta (TGF-β)-like protein which is derived from neurons and glial cells, and which has a neurotrophic effect on dopaminergic (DAergic) neurons, to nucleic acids coding for the protein, to a vector containing the nucleic acids, to host organisms containing the nucleic acids...

20060148695 - Novel angiogenic composition and use thereof: The invention relates to a composition for promoting angiogenesis, for controlling DNA synthesis of a cell, and for controlling chemotactic motility of a cell. The invention also relates to a method for treating ischemia diseases....

20060148692 - Novel protein and its dna: A protein, a polynucleotide, an antibody of the present invention, etc. are useful as, for example, a diagnostic marker for a neurodegenerative disease and so on. A compound promoting or inhibiting the activity of the protein, a compound promoting or inhibiting the expression of a gene for the above protein,...

20060148689 - Peptides with affinity for a phospholipid and uses: in which the amino acids J are chosen, independently of one another, from essential amino acids, or derivatives thereof, such that at least 50% of them are polar residues chosen from Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Lys, Orn, Pro, Ser, Thr and Tyr; the amino acids U...

20060148687 - Proteolysis resistant active vegf: The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression...

20060148696 - Protozoan derived compositions and methods for treating autoimmune disease: The instant invention relates to methods for treating a subject suffering from or susceptible to an autoimmune disease or disorder, or a disease or disorder having an autoimmune component, comprising administering to the subject an effective amount of cyclophilin or a biologically active fragment thereof....

20060148690 - Secreted peptides: This invention provides secreted active peptides, methods and compositions for making such peptides, and methods of using the peptides in detection assays, for disease diagnosis, for disease treatment and for drug development, in particular for microbial or viral infections....

20060148698 - Storage-stable fibrinogen solutions: Methods are provided for the stable storage of ready-to-use, biocompatible mammalian fibrinogen, which despite its concentration, remains available in fluid form, and which will permit long-term rapid and easy processing into a tissue adhesive preparation. Also provided is the sterile, storage-stable aqueous fibrinogen product resulting from the use of the...

20060148704 - Supplemented matrices for the repair of bone fractures: Supplemented matrices comprising a PTH releasably incorporated therein, optionally containing a granular material, are described herein. The PTH is incorporated either through covalent linkage to the matrix or through non-covalent interaction with the matrix and/or the granules. These supplemented matrices decrease the time of healing compared to autograft and or...

20060148701 - Surfactant protein c esters: Novel surfactant protein C esters suitable for preparing pharmaceutical compositions for the treatment of infant respiratory distress syndrome and adult respiratory distress syndrome are described....

20060148703 - Sustained delivery of pdgf using self-assembling peptide nanofibers: The present invention is directed to a therapeutic composition in which human PDGF is bound directly to peptides that self assemble into a biologically compatible gel. When implanted in a patient's body, the composition provides for the slow, sustained release of PDGF. The composition will be especially useful in treating...

20060148691 - Sustained release preparation for therapy of coronary stenosis or obstruction: A pharmaceutical composition for therapy of coronary artery narrowing or blockage, which comprises a sustained release preparation containing an angiogenesis factor or a gene encoding the same and a gelatin hydrogel is disclosed. Examples of the angiogenesis factor which may be used include e.g., bFGF and other FGFs, VEGF, HGF,...

20060148707 - Use of ligands to gaba beta receptors: The invention relates to the use of ligands to GABAB receptors for increasing neurotrophin levels in the central nervous system....

20060148688 - Use of na, k-atpase a-and b-subunits in bladder cancer detection and drug screening: Methods are provided for determining the malignancy of cells in a bladder carcinoma sample. Expression patterns of Na,K-ATPase α and β subunits are shown to be associated with recurrence risk in these cancers. Detection of Na,K-ATPase α and β subunits expression in bladder carcinomas provides a useful diagnostic for predicting...

20060148705 - Vegf-binding fusion proteins and therapeutic uses thereof: Nucleic acid molecules encoding fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells....

20060148711 - Molecular interactions in neurons: Inhibitors that disrupt binding between a PDZ protein and cognate ligands such as N-methyl-D-aspartate (NMDA) receptors that are involved in various neurological disorders are provided. Pharmaceutical compositions containing such inhibitors and their use in treating neurological diseases such as stroke and ischemia are also disclosed. Screening methods to identify additional...

20060148712 - Monocyte chemoattractant activity of galectin-3: Inhibitors of galectin-3 expression or activity, for administering to a subject in an amount sufficient to reduce or decrease onset, progression, severity, frequency, duration or probability of one or more symptoms associated with asthma, among other respiratory airway and respiratory mucosal disorders....

20060148710 - Oligopeptides, composition and use thereof as elicitors of the natural defences of plants: The invention relates to oligopeptides used as elicitors of the natural defences of plants in order to control fungal and/or bacterial and/or viral pathogens and/or crop pests, by means of foliar or root application or by injection. According to the invention, said oligopeptides are characterised in that they are obtained...

20060148713 - Use of exendins and agonists thereof for the reduction of food intake: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or...

20060148715 - Structural requirements for stat3 binding and recruitment to phosphotyrosine ligands: Inhibitors of Stat3 are disclosed, including small molecules and peptide mimetic inhibitors. Specific Stat3 inhibitors of the invention are useful as beta-turn mimetics. Also disclosed are pharmaceutical compositions of the Stat3 inhibitors of the invention, and methods for using the compounds of the invention to inhibit growth of a cell...

20060148714 - Therapeutic peptide-based constructs: The present invention relates generally to small peptide-based constructs, including derivatized constructs, and their therapeutic uses. The sequences of these constructs are based on a reverse subsequence derived from Domain II of bactericidal/permeability-increasing protein (BPI)....

20060148716 - Peptidic sulfonamides: The invention relates to novel peptides which are biologically active as ligands of blood platelet integrin GPIIbIIIa and the αv integrins, preferably the αvβs and αvβ3 integrin, having the formula (I): R1-Arg-X-Asp-Leu-Asp-Ser-Leu-Arg-R2 (I), in which R1 denotes H, acetyl or acyl and R2 denotes -Oh, OR3 NH2,NHR3, N(R3)2 R3 denotes...

20060148717 - Biocidal proteins: Biocidal proteins capable of isolation from seeds have been characterized. The proteins have an amino acid sequence containing the common cysteine/glycine domain of Chitin-binding Plant Proteins but show substantially better activity against pathogenic fungi, a higher ratio of basic amino acids to acidic amino acids, and/or antifungal activity which results...

20060148718 - Conjugates useful in the treatment of prostate cancer: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug...

20060148719 - Tripeptide and tetrapeptide sulfones: Tripeptide and tetrapeptide sulfones, pharmaceutical compositions containing them, their pharmaceutical use, and their preparation. The compounds are useful in potentiating the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exerting toxicity in tumor cells, elevating the production of GM progenitors in bone marrow cells, stimulating the differentiation of bone...

20060148720 - Use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus: According to the invention there is provided the use of melagatran, or a pharmaceutically-acceptable derivative thereof, for the manufacture of a medicament for the treatment of Type I diabetes....

20060148721 - Combination therapy for the treatment of dyslipidemia: The present invention relates to compositions comprising an anti-obesity agent and an anti-dyslipidemic agent useful for the treatment of dyslipidemia, dyslipidemia associated with obesity and dyslipidemia-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering...

20060148722 - Novel lincomycin derivatives possessing antibacterial activity: Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. The compounds of the subject invention may exhibit potent activities against bacteria, including Gram positive organisms, and may be useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed....

20060148724 - Genipin derivatives and uses thereof: Genipin derivatives and pharmaceutical compositions thereof that inhibit the activity of uncoupling protein-2 (UCP2) and are useful in treating deficient first-phase insulin secretion, non-insulin dependent diabetes mellitus, and ischemia in a mammal are disclosed....

20060148723 - Novel glycolipid and medicine for autoimmune disease containing the same as active ingredient: n

20060148725 - Selective 11beta hsd inhibitors and methods of use thereof: Methods for treating glucocorticoid associated states using selective 11β-HSD1-dehydrogenase, 11β-HSD1-reductase and 11β-HSD2 dehydrogenase modulating compounds are described....

20060148727 - Folate based composition for neurological and cognitive applications: New formulations for the prevention and treatment of neurological diseases and cognitive deficiencies, particularly Alzheimer's Disease comprise folate in combination with compounds chosen to address some or all of the pathways which can result in neurological deficiencies and diseases, namely inflammation, oxidative stress, glycation/dysinsulinemia, platelet function, homocysteine levels and acetylcholinesterase...

20060148728 - Novel podophyllotoxin compositions: The present invention discloses compositions comprising podophyllotoxins, analogs thereof, or derivatives thereof, and a surfactant. The invention also discloses a podophyllotoxin composition further comprising a targeting moiety. The present invention also discloses a method of delivering a podophyllotoxin, an analog thereof or a derivative thereof, to a cell by administering...

20060148726 - Pharmaceutical compositions comprising flavonoids and menthol: The present invention relates to use of certain antiviral fragrances for reduction of viruses, in particular vira causing common cold. In one embodiment, the invention relates to pharmaceutical compositions comprising an antiviral fragrance, preferably menthol. Said compositions preferably also comprise one or more flavonoids. The invention also relates to treatment...

20060148731 - 11,12-lactone bicyclolides: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the...

20060148729 - Avermectin b1 and avermectin b1 monosaccharide derivatives having an alkoxymethyl substitutent in the 4\"-or 4'-position: What is described are a compound of the formula (I): wherein n is 0 or 1; A-B is —CH═CH— or —CH2—CH2—; R1 is C1-C12-alkyl, C3-C8-cycloalkyl or C2-C12-alkenyl; R2 is for example C1-C12-alkyl, C2-C12-alkenyl or C2-C12-alkinyl; which are optionally substituted with one to five substituents selected from the group consisting of...

20060148730 - Method of treating tuberculosis: Macrolide and ketolides, and compositions containing the same, useful in the treatment of tuberculosis are disclosed. Methods of treating tuberculosis using the macrolides and ketolides, and compositions containing the same, also are disclosed....

20060148733 - Composition containing total triterpenoid saponins extracted from bamboo, and the preparation method and use thereof: The invention relates to a composition containing total triterpenoid sapogenins extracted from bamboo, the preparation method and use thereof. These total triterpenoid sapogenins are extracted from many parts of bamboo such as bamboo shavings in Gramineae by CO2 Supercritical Fluid Extraction technique. In the extract, the content of total triterpenoid...

20060148732 - Inhibition of nf-kappab by triterpene compositions: The invention provides methods for the inhibition of inflammation by providing, to a cell, in need thereof, monoterpene compositions that inhibit NF-κB. These compositions may also contain a carrier moiety that renders the monoterpene composition membrane permeable. The carrier may include triterpenoid moieties, sugars, lipids, or even additional monoterpenoid moieties....

20060148747 - Antisense antiviral compound and method for treating influenza viral infection: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. The antisense antiviral compounds...

20060148736 - Device for assaying polymorphisms of gene xpd/ercc2 for the correct administration of chemotherapy for lung cancer: The invention is encompassed in the technical sector of lung cancer treatment with antitumor drugs, and it specifically develops a diagnostic device which allows treating each patient with the most effective drug according to the polymorphism they show for the XPD gene. The assay device of the invention is based...

20060148734 - Diaminoacid-aminoacid-polyamine based gemini surfactant compounds: Diaminoacid-polyamine:peptide-based gemini compounds are disclosed. The compounds are based on diaminoacid-polyamine or diaminoacid-aminoacid-polyamine backbone with peptide groups and optionally hydrocarboxyl groups linked thereto. Uses of the diaminoacid-polyamine:peptide-based gemini compounds and methods for their production are also disclosed....

20060148745 - Dna-based aptamers for human cathepsin g: The present research is directed to the identification of non-peptidic inhibitors of cathepsin G characterised by high levels of selectivity and which can be efficaciously used in the treatment and prophylaxis of inflammatory occurrences and procoagulant conditions. The cathepsin G-inhibiting aptamers according to the invention consist of linear DNA or...

20060148740 - Mannose-6-phosphate receptor mediated gene transfer into muscle cells: The invention relates to glycoside-compound conjugates for use in antisense strategies and/or gene therapy. The conjugates comprise a glycoside linked to a compound, in which the glycoside is a ligand capable of binding to a mannose-6-phosphate receptor of a muscle cell. For example the cells are muscle cells of a...

20060148741 - Metastasis suppressor gene on human chromosome 8 and its use in the diagnosis, prognosis and treatment of cancer: The invention provides an isolated or purified ribonucleic acid (RNA) molecule comprising a nucleotide sequence encoded by a human (Tey1) metastasis suppressor gene located at p21-p12 on chromosome 8 or a fragment thereof, wherein the isolated or purified RNA molecule comprises from about 10 to about 100 nucleotides. The invention...

20060148739 - Method of evaluating compound efficacious in treating obesity: Examination of obesity or emaciation is performed based on expression levels of LCE gene or protein in a test tissue or a test cell or a polymorphism of the gene. Evaluation of compounds including screening of therapeutic agents for obesity or emaciation is performed utilizing the nature of LCE gene...

20060148735 - Methods for treating, preventing, or reducing cardiac disorders using fadd inhibitors: The present invention relates to methods for treating or preventing cardiac disorders such as heart failure, by administering to a mammal a therapeutically effective amount of an FADD inhibitor. According to the present invention, the FADD inhibitor is anti-apoptotic, anti-inflammatory, or both. Also disclosed are screening methods that make use...

20060148749 - Novel treatment of neurodegenerative diseases by altering levels of trkb isoforms and/or trkc isoforms: This invention relates to a method of treating or preventing neuro-degenerative disorders and neuro-developmental disorders by altering the ratio of the amount of full-length TrkB polypeptide to the amount of truncated TrkB polypeptides in a neuron or by altering the ratio of the amount of full-length TrkC polypeptide to the...

20060148751 - Nucleic acid derivatives: A compound which comprises a backbone having a plurality of chiral carbon atoms, the backbone bearing a plurality of ligands each being individually bound to a chiral carbon atom of the plurality of chiral carbon atoms, the ligands including one or more pair(s) of adjacent ligands each containing a moiety...

20060148746 - Nucleic acid inhibitors of glutamate receptors: The present invention relates to novel nucleic acid ligands or aptamers that bind to and inhibit the activation of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subtype of ionotropic glutamate receptors. Also disclosed is a novel combination of technologies, i.e., SELEX and laser pulse photolysis for the selection and screening of aptamers that...

20060148748 - Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met: The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are...

20060148742 - Polynucleotide delivery to cardiac tissue: A method for delivering a polynucleotide to cardiac tissue, including substantially isolating the coronary venous circulation from systemic circulation, and introducing a polynucleotide into the isolated coronary venous circulation to effect localized transfection of cardiac tissue. The polynucleotide advantageously produces a therapeutic effect, such as increasing or decreasing the expression...

20060148750 - Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol: Pharmaceutical compositions which comprise HIV Pol DNA vaccines are disclosed, along with the production and use of these DNA vaccines. The pol-based DNA vaccines of the invention are administered directly introduced into living vertebrate tissue, preferably humans, and preferably express inactivated versions of the HIV Pol protein devoid of protease,...

20060148738 - Preventive for adhesion following abdominal surgery: The present inventors discovered that oligonucleotides which suppress midkine expression and antibodies which suppress midkine activity can be used to prevent post-surgical intraperitoneal adhesions....

20060148743 - Rna interference mediated inhibition of histone deacetylase (hdac) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA) molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and...

20060148744 - Use of cis-epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce damage from stroke: The invention provides uses and methods for reducing brain damage from stroke. The uses comprise the use of an inhibitor of soluble epoxide hydrolase (sEH) for the manufacture of a medicament to reduce brain damage from stroke, as well as the use of cis-epoxyeicosatrienoic acid (EET) for that purpose. The...

20060148737 - Wound healing method and kits: Electroporation is used to enhance the wound-healing benefit provided by transfection of nucleic acids that encode cellular growth factors. Wounds which are amenable to the method include inter alia cutaneous lesions, muscular lesions, osseus lesions, burn wounds, and gastrointestinal anastamoses. Kits comprise electrodes and nucleic acids encoding cellular growth factors....

20060148752 - Method of treating soild tumors and leukemias using combination therapy of vitamin d and anti-metabolic nucleoside analogs: The present invention relates to a method of inhibiting solid tumor cell or leukemia cell proliferation by first administering to a solid tumor cell or leukemia cell either vitamin D or a derivative thereof and subsequently administering at least one anti-metabolic nucleoside analog to the solid tumor cell or the...

20060148753 - Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU...

20060148754 - Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance: The present invention relates to the use of a composition for treating, preventing and/or improving metabolic dysfunctions associated with type 2 diabetes mellitus and insulin resistance, said composition comprising acetogenic fibers...

20060148755 - Regimens for intra-articular viscosupplementation: The invention provides viscosupplementation methods for treating osteoarthritis and joint injury with HA-based viscosupplements, particularly viscosupplements with an intra-articular residence half-life shorter than 3 weeks. Viscosupplements for use in the methods of the invention may be further characterized in that they contain less than 20 mg/ml HA, at least 5%...

20060148756 - Amphiphilic macrocyclic derivatives and their analogues: Soluble amphiphilic macrocycle analogues having lipophilic groups attached to one side of the units making up the macrocycle and hydrophilic groups attached to the other side. These amphiphilic macrocyclic derivatives have the ability to self-assemble in aqueous solvent forming micelles or vesicles and can be used as hosts for the...

20060148757 - Method of inhibiting formation of volatile aldehydes and/or decomposition of fatty acids and use thereof: The present invention has objects to provide a method for inhibiting the formation of volatile aldehydes and/or the decomposition of fatty acids and use thereof. These objects are attained by establishing a method which comprises incorporating an α-oligoglucosyl α,α-trehalose(s) to a target product to inhibit the formation of volatile aldehydes...

20060148758 - Method for blood glucose control in a mammal by n-acylated glucosamines: e

20060148759 - 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses: This invention discloses 2α-methyl-19-nor-vitamin D analogs, and specifically 2α-methyl-19-nor-1α-hydroxy-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as...

20060148760 - Method for the sysnthesis of compounds of formula i and their uses thereof: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated...

20060148761 - Lipids: Bipolar lipids are described which are able to form complexes with polyanions. The lipids comprise a cationic head linked to a hydrophobic backbone and a hydrophilic tail and are capable of self assembly to form stable complexes in aqueous solutions. The lipids are of particular use for the delivery of...

20060148763 - Compounds and methods for regulating triglyceride levels: The present invention provides a method of administering vitamin B6 related compounds for treatment of hypertriglyceridemia. Vitamin B6 related compounds include pyridoxal, pyridoxal-5′-phosphate, pyridoxamine, a 3-acylated analogue of pyridoxal, a 3-acylated analogue of pyridoxal-4,5-aminal, and mixtures thereof. Embodiments of the present invention also comprise co-administering a lipid lowering agent, such...

20060148762 - New crystalline form of the sodium salt of 3-pyridyl-1-hydroxyehtylidene-1,1-bisphosphonic acid: The present invention relates to a crystalline, hydrated form of the sodium salt of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid. The hydrate contains from 6.4 up to 22 weight % of sodium and 15 up to 23 weight % of crystalline water if the sodium content is lower than 7.5 weight %, based on...

20060148764 - 5-phenypyrimidines their preparation compositions comprising them and their use: in which Ra, Rb and Rc are as defined in the description; X is halogen, alkyl, alkoxy or haloalkyl; and m is an integer from 1 to 5; processes for preparing these compounds, compositions comprising them and their use for controlling harmful fungi are described....

20060148765 - 7-substituted fused ring tetracycline compounds: 7-substituted fused ring tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted fused ring tetracycline compounds are described....

20060148766 - Composition comprising minocycline as an effective component for prevention and treatment of dementia, and learning and memory impairments: The present invention relates to a composition for preventing and treating dementia and memory impairment, which contains minocycline as active ingredient. The composition of the present invention has an effect of inhibiting brain cell death and memory impairment, which are induced by amyloid beta-protein and C-terminal protein. Thus, the composition...

20060148767 - Use of acyl salicylates as heat shock inducers: The invention relates to acyl-salicylates as heat shock response inducers and the use thereof as active ingredients in cosmetic and/or pharmaceutical preparations....

20060148769 - (20s)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin d3 and their uses: This invention discloses (20S)-1α-hydroxy-2α-methyl-19-nor-vitamin D3 and (20S)-1α-hydroxy-2β-methyl-19-nor-vitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well...

20060148768 - Vitamin d3 lactone derivatives: [wherein R1 refers to hydrogen atom, C1-C6 alkyl group optionally substituted with hydrogen group or C1-C6 alkoxy group optionally substituted with hydroxyl group, R2a and R2b refer to hydrogen atom, C1-C10 alkyl group optionally substituted with hydroxyl group, C6-C10 aryl group optionally substituted with hydroxyl group or C7-C12 aralkyl group...

20060148772 - Combination: The present invention provides a combination for the treatment of a disease or condition which responds to dual EGFR and VEGF protein tyrosine kinase inhibition and either aromatase inhibition or inhibition of estrogen action, in particular a proliferative disease, especially a malignant disease, such as breast cancer, comprising a dual...

20060148770 - Combinations for the treatment of rheumatoid arithritis: The invention features a method for treating a patient diagnosed with rheumatoid arthitis by systemically administering an azole and a steroid to the patient. The invention also features a pharmaceutical composition containing an azole and a steroid for the treatment of rheumatoid arthritis....

20060148771 - Medicinal compounds: A compound of formula (I) or a salt, solvate, or physiologically functional derivative thereof, wherein: m is an integer of from 2 to 8; n is an integer of from 2 to 5; with the proviso that m+n is 4 to 10; R4 and R5 are independently selected from hydrogen...

20060148773 - Novel steroidal antiestrogens and antiandrogens and uses thereof: The present invention comprises the design, synthesis and development of a new class of chemotherapeutic agents for prophylactic and therapeutic treatments in a mammal, particularly a human, believed to be at risk of suffering from a hormone-responsive disorder. In an embodiment of the invention, such treatments include therapeutic compositions comprising...

20060148774 - Hypoglycemic agent: A hypoglycemic agent comprising a compound selected from the group consisting of 24-alkylcholestan-3-ones and 24-alkylcholesten-3-ones (for example, 24-alkylcholestan-3-ones, 24-alkylcholestmonoen-3-ones, 24-alkylcholestdien-3-ones, 24-alkylcholesttrien-3-ones, or 24-alkylcholesttetraen-3-ones, preferably 5-campesten-3-one) as an active ingredient. The agent can be used for improvement of hyperglycemia resulting from diseases such as diabetes, and can be used as a...

20060148775 - Carbonate and carbamate modified forms of glucocorticoids in combination with b2 adrenergic agonists: h

20060148777 - Anthraquinone and its derivatives: There is disclosed a compound of formula (I) wherein each of X1 and X2 are independently NH-A-NR1R2, and wherein A is A C2-8 alkylene and R1 and R2 are independently selected from hydrogen, C1-4 alkyl, C2-4 hydroxy-alkyl and C2-4 aminoalkyl, or R1 and R2 together form a C2-6 alkylene group...

20060148776 - Drug formulations having long and medium chain triglycerides: Drug formulations having emulsifying agents and both medium and long chain triglycerides are described. In preferred embodiments, the long chain triglycerides negate or lessen deleterious central nervous system effects that are caused by medium chain triglycerides....

20060148778 - Regioselective hydroxylation, functionalisation and protection of spirolactams ii: The invention provides highly functionalised spiro-fused azetidinones having a cyclohexane moiety with the desired number of protected or unprotected hydroxyl groups or carbonated structures, which are introduced with high stereo and regioselectivity, as well as processes for their obtention....

20060148779 - Monocyclic anilide spirohydantoin cgrp receptor antagonists: The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the...

20060148780 - Diazepanes derivatives useful as ifa inhibitors: Pharmaceutically active diazepanes, e.g. useful for treating disorders or diseases mediated by LFA-1/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions....

20060148787 - Compositions for weight management: Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are...

20060148784 - Medicine for treating gastrointestinal disorder in a non-human mammal: A method and a medicine for treating a non-human mammal having a gastrointestinal disorder that includes fecal incontinence and/or irritable bowel syndrome are provided. The method includes administering a dose of the medicine to the mammal. The medicine includes a tricyclic antidepressant and a stool softener....

20060148785 - Medicine for treating gastrointestinal disorder including fecal incontinence: A method and a medicine for treating a human having a gastrointestinal disorder that includes fecal incontinence are provided. The method includes administering a dose of the medicine to the human. The medicine includes a tricyclic antidepressant and a stool softener....

20060148786 - Medicine for treating gastrointestinal disorder including irritable bowel syndrome: A method and a medicine for treating a human having a gastrointestinal disorder that includes irritable bowel syndrome are provided. The method includes administering a dose of the medicine to the human. The medicine includes a tricyclic antidepressant and a stool softener....

20060148782 - Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both: A method and a medicine for treating a mammal, such as a person, cat, or dog having a urinary disorder that includes urinary incontinence and/or urinary urgency are provided. The method includes administering a dose of the medicine to the mammal. The medicine includes a tricyclic antidepressant and a stool...

20060148781 - Method and medicine for treating gastrointestinal disorder in a non-human mammal: A method and a medicine for treating a non-human mammal having a gastrointestinal disorder that includes fecal incontinence and/or irritable bowel syndrome are provided. The method includes administering a dose of the medicine to the mammal. The medicine includes a tricyclic antidepressant and a stool softener....

20060148783 - Method and medicine for treating gastrointestinal disorder including fecal incontinence: A method and a medicine for treating a human having a gastrointestinal disorder that includes fecal incontinence are provided. The method includes administering a dose of the medicine to the human. The medicine includes a tricyclic antidepressant and a stool softener....

20060148788 - Pyrrolobenzodiazepines: m

20060148790 - Benzodiazepine cgrp receptor antagonists: (where variables R1, R2, R3, R6, R7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed...

20060148791 - Glutamate receptor antagonists: h

20060148789 - Novel diazabicyclic aryl derivatives: This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of...

20060148792 - Substituted 1,4-benzodiazepines and uses thereof: i

20060148793 - Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them:

20060148794 - Quinoline derivatives:

20060148795 - Novel compounds for use in weight loss and appetite suppression in humans: Phenolic compounds with a phenolic molecule to which are covalently linked an oxygen-containing group, a nitrogen or another oxygen containing group, and a C1-C4 alkoxy group, obtainable from monocotyledonous plants, or by chemical synthesis, have been found to act as weight loss agents, appetite suppressants, mood enhancers and adjunctive therapy...

20060148796 - 6-substituted imidazopyrazines: e

20060148797 - Benzoyl-tetrahydropiperidine derivatives:

20060148798 - N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands:

20060148799 - Substituted p-phenyl carbamates: Novel substituted p-phenyl carbamates, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which modulation of the activity of hormone sensitive lipase...

20060148800 - Pyrimidines as plk inhibitors: v

20060148801 - Anti-tumor compounds:

20060148802 - Use of compounds that stimulate cgmp: The invention relates to the use of compounds that stimulate cGMP, in particular imidazo[1,3,5]triazinones, for producing a medicament for the treatment and/or prophylaxis of diseases, in which the clinical picture can be improved and/or cured by the improvement of the micro-circulation of tissue containing a phosphodiesterase that metabolises cGMP....

20060148805 - Opthalmic compositions for treating ocular hypertension: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect...

20060148806 - Opthalmic compositions for treating ocular hypertension: A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor....

20060148804 - Pde4 inhibitors for the treatment of neoplasms of lymphoid cells: The invention relates to the use of certain PDE4 inhibitors alone or in combination with one or more differentiation inducing agents and/or an agent effective in raising intracellular concentrations of cAMP or a stable analogue of cAMP in the preparation of pharmaceutical compositions for the treatment of neoplasms of lymphoid...

20060148807 - Pyrrolo[1,2b]pyridazine compounds and their uses: e

20060148803 - Substituted peptides useful in the treatment of alzheimer's disease: Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of compounds of formula (I), wherein Ar, W, Z, Q, R1, U, and L, are as herein defined....

20060148808 - Substituted heterocycle fused gamma-carbolines: or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or...

20060148809 - Pyridazine derivatives as ligands for gaba receptors: A class of pyridazine derivatives, substituted in the 4-position by an optionally substituted heteroaromatic ring, being selective ligands for GABAA receptors, in particular having high affinity for the α2 and/or α3 and/or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central...

20060148810 - Treatment of amm: The present invention relates to a method of treating a warm-blooded animal, especially a human, having agnogenic myeloid metaplasia (AMM), especially agnogenic myeloid metaplasia which is resistant to conventional chemotherapy....

20060148811 - Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent: e

20060148812 - Inhibitors of c-fms kinase: wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast...

20060148813 - Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit: The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors....

20060148814 - Therapeutic agents useful for treating pain: (wherein X is O or S and R1-R5 are disclosed herein) or a pharmaceutically acceptable salt thereof (each being a “Piperazine Compound”), pharmaceutical compositions comprising a Piperazine Compound and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a...

20060148815 - 4-phenyl-1-piperazinyl, -piperidinyl and-tetrahydropyridyl derivatives: h

20060148816 - 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases: In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17β-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,...

20060148817 - Pyrazole compounds: Compounds of formula (IA) or (IB) or a salt, N-oxide, hydrate or solvate thereof are inhibitors of HSP90, and are of value in the treatment of diseases responsive to HSP90 inhibition such as cancers. In the formulae, Ar is an aryl, aryl(C1-C6 alkyl), aryl(C1-C6 alkyl), heteroaryl, heteroarylaryl(C1-C6 alkyl), or heteroarylaryl(C1-C6...

20060148819 - Chemical compounds: The invention relates to compounds of the formula (I): wherein: ring C is 9 or 10-membered bicyclic heteroaromatic group containing at least one nitrogen atom in the ring attached to Z and optionally containing a further 1-3 heteroatoms, selected independenly from 0, S, and N, with the proviso that ring...

20060148818 - Novel tetraydrospiro(piperdine-2,7'- pyrrolo{3,2-b}pyridine derivatives and novel in-dole derivatives useful in the treatment of 5-ht6 receptor-related disorders: The present invention relates to compounds of formula (I): Formula (I) wherein U, P, W1, W2, W3, v, Y, Z, Rm, and Rm′ are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation...

20060148820 - Chroman derivatives and uses thereof: e

20060148821 - N,n-disubstituted diazocycloalkanes: (R1=halogen, R2=(C3-C8)-cycloalkyl, R3=(C1-C4)-alkoxy or (C1-C4)-haloalkoxy group, m is 1 or 2 and n is 1 or 2, have affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract...

20060148822 - 5-phenylthiazole derivatives and their use as p13 kinase inhibitors: 1

20060148823 - Tricyclic delta-opioid modulators: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described....

20060148824 - Protein kinase inhibitors: e

20060148826 - Stable aqueous solutions of risperidone and methods for their preparation: The technical field of the present invention relates to stable aqueous solution of risperidone for oral administration; and process for preparation thereof....

20060148825 - 1-[alkyl], 1-[(heteroaryl) alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives: e

20060148827 - Methods of treating patients suffering from movement disorders: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the...

20060148828 - Combination comprising a cdk inhibitor and a topoisomerase 1 inhibitor for the treatment of cancer and other proliferative diseases: A first aspect of the invention relates to a combination comprising a CDK inhibitor and CPT-11. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and CPT-11 as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the...

20060148829 - Means for inducing differentiation of supernumerary hair cells and deiters' cells in the developing organ of corti: Use of at least one kinase inhibitor for making drugs for inducing differentiation of supernumerary hair cells and Deiters' cells in the developing organ of Corti....

20060148830 - Lpa receptor antagonist: (wherein the symbols are as defined in the description), or a non-toxic salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by...

20060148831 - 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor....

20060148832 - Use of 2-amino-2h-quinazoline derivatives for producing therapeutic agents: The invention concerns the use of 2-amino-2H-quinazoline derivatives of general chemical formula (I), wherein R1 indicates an alkyl group with 1-5 carbon atoms and R2, R3, R4 and R5, independently of one another, each indicate a chlorine or hydrogen atom, as well as their pharmaceutically compatible salts, for producing therapeutic...

20060148834 - Novel coumarin-amide derivatives and its preparation, said drug composition and its use: The present invention relates to novel coumarin derivatives, their carboxamides, pharmaceutical compositions containing them and their uses as drugs for kidney protection, treating drugs of hypertension, cardio-cerebrovascular diseases, non-insulin dependent diabetes, tumor, pre-cancerous lesion, and edemas....

20060148833 - Use of chymase inhibitors for the prevention and/or treatment of arterio-venous graft failure: Disclosed is a method of treating A-V graft failure in a subject in need of such treatment, said method comprising administering to said subject an effective amount of an agent that inhibits the production, release or neo-intima generating effects of chymase, wherein said effective amount of said agent is an...

20060148835 - Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression: Methods are provided for treating disorders associated with mGlu receptors by simultaneously inhibiting at least two mGIuRs belonging to at least two different groups. In one embodiment, there are provided methods for treating a disorder associated with MGlu receptors 2, 3, and 5, including administering to a subject in need...

20060148836 - Pyridyl-substituted spiro-hydantoin compounds and use thereof: t

20060148837 - Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction: The present invention relates to compositions comprising an antitussive, a decongestant and an expectorant, and in a specific embodiment comprising hydrocodone, phenylephrine hydrochloride and guaifenesin, wherein the composition may be substantially free of added sugar and added alcohol, and methods for using these compositions for the treatment of patients suffering...

20060148838 - Novel pyrrolodihydroisoquinolines useful in the treatment of cancer: The invention relates to novel pyrrolodihydroisoquinoline derivatives, which are efficacious inhibitors of cellular (hyper)proliferation and/or inducers of apoptosis in cancer cells....

20060148839 - New pharmaceutical compositions based on anticholinergics and tace-inhibitors: The present invention relates to novel pharmaceutical compositions based on anticholinergics and TACE (TNF alpha converting enzyme) inhibitors, processes for preparing them and their use in the treatment of respiratory diseases....

20060148841 - Pharmaceutical composition comprising combination of non-alkaloid and alkaloid-based component for treating skeletal muscle spasm: A medicinal composition that may include an effective amount of a non-alkaloid and an alkaloid-based skeletal muscle relaxant are provided. A method that includes administering the medicinal composition to a human in an amount effective to treat a muscle spasm is provided. The medicinal composition may include an alkaloid-based and...

20060148840 - Pyrrolodihydroisoquinolines as pde10 inhibitors: The invention relates to novel pyrrolodihydroisoquinoline derivatives, which are efficacious inhibitors of PDE10....

20060148842 - Nepetalactams and n-substituted derivatives thereof: Nepetalactams and N-substituted derivatives thereof are prepared by alkylation of metallated lactams. Nepetalactams and N-substituted derivatives thereof have utility as insect repellents....

20060148843 - Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (vr1) and uses thereof: wherein X1-X6, R5-R7, Z1 and L are as defined in the description. The resent invention also discloses a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain, urinary incontinence, bladder overactivity, and inflammatory thermal hyperalgesia in mammals, and pharmaceutical compositions including those compounds....

20060148845 - Anti-infective biaryl compounds: Compounds represented by the formula (I), where R1, R2, R3, R4, R5, and Q are as defined herein, exhibit activity against infectious pathogens....

20060148846 - Crystalline forms of a factor xa inhibitor: The instant invention provides crystalline forms of 3-(1-hydroxy-1-methyl-ethyl)-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one and its solvates thereof; processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions....

20060148844 - Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation: A therapeutic and/or preventing agent for a disease due to vascular constriction or vasodilation comprising a EDG-5 modulator. Since EDG-5 modulator specifically binds EDG-5 and shows antagonistic or agonistic action, EDG-5 antagonist is useful for treating and/or preventing for a disease due to vascular constriction, for example, cerebrovascular spasmodic disorder...

20060148847 - Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel 8-aza-bicyclo[[3.2.1]octane derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention....

20060148848 - Compounds and methods for treating cancer and inflammation: Methods of using isoquinolone derivatives to treat cancer or inflammation in a mammal and pharmaceutical compositions containing such derivatives are disclosed....

20060148849 - Quinoline derivatives, process of synthesis and medicaments containing these derivatives: Ra is H or —(CH2)n′—Y, with n′=0, 1, 2 or 3 and Y and —CH3, —COOH, —COOR, —CN, —OH, —OR, SR, or an aryl group optionally substituted with Rb, R and R′ represent a linear or branched alkyl chain of 1 to 4 C, and their pharmaceutically acceptable salts. Application...

20060148850 - 4-{'3-(sulfonylamino) phenyl!'1-(cyclymethyl) piperidin-4-ylidene! methyl}benazmide derivativess as delta opioid receptor ligands for the treatment of pain, anxiety and functional gastrointestinal disorder: Compounds of general formula: (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain....

20060148851 - Fexofenadine crystal form and processes for its preparation thereof: Provided is a crystalline form of fexofenadine free base and processes for its preparation....

20060148852 - Visual function disorder improving agents: The present invention provides a visual function disorder improving agent containing a compound having Rho kinase inhibitory activity, particularly (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, as an effective component. This agent has axon of the retinal ganglion cellal extension promoting action and optic nerve cell regeneration promoting action, and is useful for the treatment of...

20060148853 - Bisulfite conversion reagent: Disclosed, among other things, are packaged bisulfite solutions comprising bisulfite reagent in an oxygen-impermeable container and methods....

20060148856 - Benzimidazole derivatives and their use for modulating the gabaa receptor complex: This invention relates to novel benzimidazole derivatives of formula (I), pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAA receptor complex, and in particular...

20060148855 - Carboxamide derivatives: i

20060148854 - Chemical compounds: Benzimidazolyl-pyridine derivatives, which are useful as SGK-1 inhibitors are described herein. The described invention also includes methods of making such benzimidazolyl-pyridine derivatives as well as methods of using the same in the treatment of diseases mediated by inappropriate SGK-1 activity....

20060148857 - Tetrahydrocarbazole derivatives and their pharmaceutical use: The present invention relates to novel compounds that are useful in the treatment of human papillomaviruses, and also to the methods for the making and use of such compounds....

20060148858 - 1, 2-azole derivatives with hypoglycemic and hypolipidemic activity: A compound represented by the formula (1) wherein ring A is a ring optionally having 1 to 3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, —O—, —S— and...

20060148859 - Substituted pyridyloxyalkylamides and their use as fungicides: Fungicidal compounds of the general formula (1), or the corresponding pyridine N-oxide, wherein X, Y, R1, R2, R3, R4 and R5 are as defined in the description....

20060148860 - Substituted p-phenyl carbamates: Novel substituted p-phenyl carbamates, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which modulation of the activity of hormone sensitive lipase...

20060148861 - Amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid: The invention relates to new 2,2,3,3-tetramethylcyclopropane carboxamide derivative compounds, pharmaceutical compositions thereof and uses thereof for treating psychotic disorders, neurodegenerative diseases, epilepsy and pain....

20060148862 - Novel compounds that modulate ppary type receptors and cosmetic/pharmaceutical compositions comprised thereof: e

20060148863 - Substituted 1,2,4-oxadiazoles, compositions and methods of use: Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith....

20060148864 - 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, compositions, and methods for the use thereof: Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith....

20060148865 - Preparation of chemical compounds: The present invention is directed to processes for the preparation of N-(3R, 3aS, 6aR)-hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-, (4S,5R)-4-[4-(2-methylthiazolo-4-methyloxy)-benzyl]-5-i-butyl-[(3,4-methylenedioxyphenyl)sulfonyl]-aminomethyl-2,2-dimethyl-oxazolidine....

20060148866 - Novel process for preparing pramipexole and its optical isomeric mixture by reduction with sodium triacetoxyborohydride: A novel process is provided for producing pramipexole base or its optical isomeric mixture as defined hereinabove i.e. (R,S)-2-amino-6-propyl-4,5,6,7-tetrahydrobenzothiazole avoiding the use of borane tetrahydrofuran complex and using a more convenient reducing agent like sodium triacetoxyborohydride instead. The provided process comprises reacting the starting material (S)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole or its optical isomeric...

20060148867 - Antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof: n

20060148869 - Halogenated biaryl heterocyclic compounds and methods of making and using the same: The present invention relates generally to the field of anti-infective anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of compounds having at least one halogenated hydrocarbon moiety, a biaryl moiety, and at least one heterocyclic moiety, that are useful as such agents....

20060148868 - Zolmitriptan polymorphs: Crystalline polymorphic forms of zolmitriptan, solid amorphous zolmitriptan, and processes for preparing them....

20060148871 - Metabolic stabilization of substituted adamantane: The present invention is directed to the method of increasing the metabolic stability of adamantane containing compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 (11-beta-HSD-1) enzyme. The stability is achieved by substitutions of the adamantane ring....

20060148870 - Process for preparing olmesartan medoxomil at ph higher than 2.5: The present invention provides a process for preparing olmesartan medoxomil at pH higher than 2.5....

20060148872 - 2-((2-thioxo-2,3-dihydro-1h-imidazol-4-yl)methyl)-3,4-dihydronaphthalen-1(2h)-one: e

20060148873 - Low-temperature-stable preservatives: A liquid, cold-temperature-stabilized preservative is based on carbendazim or a salt thereof, which includes, as low-temperature stabilizer, at least one aromatic alcohol and/or at least one aromatic glycol ether and/or a pyrrolidone....

20060148875 - Agent for prophylaxis and treatment of diabetic complications: The present invention relates to an agent for the prophylaxis and treatment of diabetic complications comprising, as an active ingredient, 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for the prophylaxis and treatment of diabetic complications comprising...

20060148874 - Compounds for use in the treatment of aids and other viral diseases and hiv-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions: or salts or hydrates thereof in a carrier which minimizes micellar formation or van der Waals attraction of molecules of said compound. The invention also provides S enantiomeric forms of such compounds which possess the ability to inhibit cell growth whilst being of low toxicity to such cells and methods...

20060148876 - Nr3b1 nuclear receptor binding 3-substituted pyrazoles: The present invention relates to compounds according to the general formula (I) which bind to the NR3B1 receptor and act as antagonists or agonists of the NR3B1 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and the...

20060148877 - Pharmaceutical formulations of celcoxib: Liquid formulations of celecoxib have been found to provide faster pain relief than conventional solid formulations of celecoxib. The present invention provides combinations of excipients in which celecoxib is highly soluble for formulation as pharmaceutical compositions....

20060148878 - Pseudopolymorphic forms of carvedilol: The present invention is concerned with pseudopolymorphic forms of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole (carvedilol) or of optically active forms or pharmaceutically acceptable salts thereof, processes for the preparation thereof and pharmaceutical compositions containing them....

20060148881 - Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity,...

20060148880 - Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them: in which R1 to R6 have the meanings stated in the claims. The inventive compounds are suitable as antiarrhythmic medicaments with a cardioprotective component for infarction prophylaxis and infarction treatment and for the treatment of angina pectoris. They also inhibit in a preventive manner the pathophysiological processes associated with the...

20060148879 - Pseudopolymorphic forms of carvedilol:

20060148882 - Methods of using and compositions comprising pde4 modulators for treatment, prevention and management airway inflammation: Methods of treating, preventing, and managing airway inflammation and other airway or pulmonary diseases and disorders are disclosed. Specific methods comprise the administration of a PDE4 modulator, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, alone or in combination with a second active agent and/or other conventional therapies....

20060148883 - Medicaments for the treatment or prevention of fibrotic diseases: t

20060148884 - Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof:

20060148885 - Medicinal composition: The present invention provides a pharmaceutical composition which is useful in the treatment for bladder irritative symptoms accompanied by benign prostatic hyperplasia and the like, and comprises 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide or a pharmaceutically acceptable salt thereof, and an α1-adrenoceptor antagonist....

20060148887 - Chemical compounds: The present invention discloses compounds of Formula I. The present invention also discloses beta-3 agonists of formula I and methods for treating beta-3 mediated diseases and condition using the compounds of formula I, in particular methods for treating diabetes or obesity....

20060148886 - Methylthiophene carboxanilides: e

20060148888 - Chroman derivatives and uses thereof:

20060148890 - Substituted furochromene compounds of antiinflammatory action:

20060148889 - Substituted furochromenes, preparation thereof and their antiinflammatory action: to the use of the compounds of the formula (II) as suitable precursors for the preparation of the compounds of the formula (I) as well as to use of the compounds of the formula (I) and of the compounds of the formula (II) as therapeutically active agents in the prophylaxis...

20060148891 - Formulations of thiomolybdate or thiotungstate compounds and uses thereof: Formulations of thiomolybdate or thiotungstate derivatives, methods of making formulations of thiomolybdate or thiotungstate derivatives, solid dosage forms of thiomolybdate or thiotungstate analogues, methods of making solid dosage forms of thiomolybdate or thiotungstate analogues and methods of using solid dosage forms of thiomolybdate or thiotungstate derivatives to treat or prevent...

20060148892 - Process for preparing gamma-cyhalothrin: A process for the preparation of gamma-cyhalothrin comprising steps of a) chlorinating 1R cis-Z 3-(2-chloro-3,3,3-trifluoro-1-propenyl)-2,2-dimethyl cyclopropanecarboxylic acid to give 1R cis-Z 3-(2-chloro-3,3,3-trifluoro-1-propenyl)-2,2-dimethyl cyclopropanecarboxylic acid chloride and b) esterifying 1R cis-Z 3-(2-chloro-3,3,3-trifluoro-1-propenyl)-2,2-dimethyl cyclopropanecarboxylic acid chloride with the (S)-cyanohydrin of 3-phenoxy benzaldehyde (III)....

20060148893 - Chemical compounds: This invention relates to non-steroidal compounds that are or are believed to be modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds....

20060148894 - 12-aryl prostaglandin analogs: i

20060148895 - New composition use and method: At least one alkyl paraben is used in an aqueous antimicrobial preservation composition for eliminating or reducing the microbial content of a microbially contaminated separation matrix, which is to be used in a housing of a separation device, the separation matrix being microbially contaminated. Also, in a method of producing...

20060148896 - Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia: The present invention relates to the use of an alkanoyl L-carnitine, or pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of anhedonia....

20060148897 - Method for sterilization using in situ gelling materials: A method for sterilizing a female or male patient is provided. The method comprises introducing into a reproductive duct of the patient a composition comprising a nucleophilic component, such as a thiol, and a component containing a conjugated unsaturated bond, such as an acrylate. The composition crosslinks within the reproductive...

20060148898 - Curing and prophylactic agent applied during the use of alcohol and psychoactive substances: The invention relates to medicine and is directed at developing means and methods for narcological practice and for preventive measures in order to reduce the risk of falling sick with such menacing modem diseases like dependence diseases, in particular alcoholism, narcomania and toximania. Said invention provides for using already known...

20060148899 - Ophthalmic compositions and methods of using the same: Ophthalmic compositions are provided that comprise or consist essentially of (a) ketotifen or a ketotifen salt, (b) a non-ionic tonicity agent, and (c) water. The concentration of ketotifen or the ketotifen salt is preferably from 0.01% to 0.05%. The non-ionic tonicity agent is preferably glycerol and the concentration of the...

20060148900 - Method for treating a mammal by administration of a compound having the ability to release co, compounds having the ability to release co and pharmaceutical compositions thereof: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached...

20060148901 - Acylated 4-amidino-and-4-guanidinobenzylamines for inhibition of plasma kallikrein: where P4 is a monosubstituted or polysubstituted or unsubstituted benzylsulfonyl group, P3 is a monosubstituted or polysubstituted or unsubstituted, natural or unnatural α-amino acid or α-imino acid in the D configuration, P2 is a monosubstituted or polysubstituted or unsubstituted, natural or unnatural α-amino acid or α-imino acid in the L...

20060148902 - Process for the preparation of nateglinide, preferably in b-form: The present invention relates to a process for the preparation of nateglinide, preferably in B-form, substantially free from the H-form, comprising three steps starting from D-phenylalanine methyl ester or a salt thereof....

20060148903 - Capsaicinoid gel formulation and uses thereof: The present invention provides capsaicinoid gel formulations and methods for relieving pre- and post-surgical pain at a site in a human or animal by administering at a surgical site in a human or animal in need thereof a dose of capsaicinoid gel in an amount effective to attenuate post-surgical pain...

20060148904 - Anti tubercular drug: compositions and methods: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis....

20060148905 - Methods for treatment of beta-amyloid protein-induced ocular disease: The invention provides methods for treating beta-amyloid protein-involved ocular disease including age-related macular degeneration and glaucoma, pharmaceutical compositions and compounds useful for the same, and the use of these compounds for the manufacture of a medicament for treating the same. More particularly, the invention relates to the use of natural...

20060148906 - Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid: The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid....

20060148907 - Topical antinflammatory preparations of y-terpinene: An anti-inflammatory agent comprising from 0.01-1.0% γ-terpinene in a pharmaceutically acceptable vehicle....

20060148908 - Supressant of toxicity induced by cancer chemotherapeutic agent and composition of cancer chemotherapeutic agent containing the same: Disclosed are a suppressant of toxicity such as hepatotoxicity and nephrotoxicity, induced by cancer chemotherapeutic agent, and a composition of cancer chemotherapeutic agent containing the suppressant. The suppressant of toxicity induced by a cancer chemotherapeutic agent contains xanthorrhizol as an active ingredient. Xanthorrhizol shows an excellent ability in suppressing ill...